var title_f9_27_9648="Multilobulated mass CT";
var content_f9_27_9648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal Hodgkin's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hodgkin's disease, nodular sclerosis variant, presenting as a multilobulated mass in the anterior mediastinum. The enlarged lymph nodes are homogeneous and tend to be matted together.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9648=[""].join("\n");
var outline_f9_27_9648=null;
var title_f9_27_9649="Piribedil: International drug information";
var content_f9_27_9649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Piribedil: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pronoran (RU);",
"     </li>",
"     <li>",
"      Travastal (AR, BR, DE, EG, FR, GR, IN, MY, PT, SG, TH);",
"     </li>",
"     <li>",
"      Travastan (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4146049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-Parkinson's Agent, Dopamine Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4146050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Parkinson's disease, either as monotherapy  without levodopa or in combination with levodopa therapy; pathological cognitive deficits in the elderly",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4146052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Parkinson's disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Initial: 50 mg/day for 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dose adjustment: Dosage may be increased weekly:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Monotherapy: 150-250 mg/day in 3-5 divided doses with meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combination with levodopa: 50-150 mg in divided doses with meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4146053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, sustained release: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10519 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9649=[""].join("\n");
var outline_f9_27_9649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302629\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4146049\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4146050\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4146052\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821140\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4146053\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10519\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10519|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_27_9650="Axial MRI LSS";
var content_f9_27_9650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial MRI in lumbar spinal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDye+Mu8urHknAz3qmzTcy+axbpyatXUrPLsUDeWP4VXkjZu4wnJHqaAHCSZBsiZsEZJz3rQtZXXaNrMB1qpapJMw8obXXnbWjbljO0pwCBgigCw/2kphGPPOAaTEkTo4Z9zDBOelT2TSpvZgGc9D1odJZH+Q8dWBoAjQPvkYu74GSc06LznT92SFPXB6VI6zSFVhxGMcn1qzaWcgmLRlAEXJGetAFNmY5w7bE6nPU1JuEgjmfK/wAIweaJPv7pAAm77oqa3EcjMrnAP3aAK43ASR/MRncDnpVaVnk2Fyw5xuzWlJIsIcA4YLkD1FVYnWSFSSHLHBX0oAjuFmjlRppN0Y+7g1YVSJFljkLlhkjNWHggeRYZQU+TII6VVhjSKVghIUDOfWgCJpCZJXlJAB+4DUkKyXBHln5QM/OcYpWaN7eQsn78vwfQVGAquTcPsjRe3egBqyO0sofLIOhzUMV2y7g5O88cGsu4vmkZlhOxGPy+9V42mSTDDLDq3pQBvz4a2ZEDeZ1zmiNpjbQ+W5LgEYJrKsbiZJcu+5QcH3rTV8s6FQo6BqALDSyJEuHJfsAelSTXHnBYDvMhH3j2qCOKOOTY7EEc59a0ZHTdHGGAdxwRQBShRwP38pfnuajW2LrKiyE5OQM9qmjt1l5Z/mB5GasNFGX3wja23BPvQBl3FtKxQyMwReAM02O3ldZQWZo+/JrUJdIVkmHmKp/OllkYyAxIqJIOVoAp2Vq0ZjSQsEYZU5q3ukjuIoix2Y+/mmZdn3FgwQYAzSM4kMYL4AHIHagCV5JZ7h4nJ2LwDmstL8WbzQhjuY8ZNbLHz4Sluq4HBfPNc9dadIHkdtrDOFJPWgDYs2LQhsc5+bmql7aQ+ZMySyKo54NFsRZWkCyOGfrIM1YguLaa5mkyDG/ASgCpZlpoiWlYRKflGeTUepLJMwaMuyjqM1pWtjHHc+ZKflAO1BVmyRUB8xRlzx7UAVdPMi2tuszHBztDGrsU0qRzbHyg9DTJVWSd45QQg+6RTZ5Fth5Wwqr+lAFG5vSXO75VHoajj1KL5wsjqqjrmsbVGla7ZBgZ9TVdv3e2NvmY/ePpQBpy6scBBJI+TxmoG1W5liIXIJ44NZxQK/zOeelOUFNuWK57DvQBdW/nxgOWReoJ6VFNqE7FVSV1Ocg1XjO4/N8meDjv9ab5m3sSQehoA1JNSnCREyGQg85NX4tSTAkLPvPRe1c8pMgI4GOQM8VLFKw47dj70AdUvmuYh5p3EhmwegorAs7uSK5csc7gAaKAInjSTezHbMpOB2NRhWVslBu9u1aM1qxkHy7gWOD706ys/LeSW4PyjqKAI7bJuIzG21v4sd60YIYpDIgfBY/rVVFjEhaFhtHLZ9Ke93HG37pRuPINAFr7OYwFWQgr1NLcXQiQZ+aNuC3eq11qaSOqoAWVcuay5btRIQ2do+cDtQBsfbAiYbJUjA4pq3CKu3zGzjOfSsRLmWd2kUgDGAM02GaTy2eRiMHBX1oA6KNgkRbPm7untQUEy/un6dcdjXPC9YSbQ7IpH3RzVm31FYysMe5R1LY60Ab56p5g3Hbj61BEsSb18vyyDUK3oluEIkwy8Cr32yCVGjZcyn+LFAEEMlyzup+cZwufSnSLKXUIFUKPmPvTnRomT5u2ay9Uu3J8mPhm5JBoA0YGSJZWfDM/6GsC9mkAZJ2LKemK0YFY2LbTkr97PU1mXCyht2Aq9FBoAoEgbc5JHQVLHJIzHcxx3zSsrllBAJFEgdkZ8DC8YFAEsc6oGXGAehqcXu6Iq+4le+KomMLabnB3EgqfSnPJIScAYNAGna35uCo2DJ45rYiSH7CJBlrhD09K5qzVjImPvE8+1bl+z2EJAIzIOQDQBYeWLcxiz05NVjqDmMRxhVG7BOe1YhupYkI3/KenNVhJvOSTvoA27nU874hIditimx6ntfcSHCjHNY+8gbdo3EckmmIiiMg8Z5zQBdnumBMkcjb37dlqGG4lyQ0pGep9ajZvkUj7vrUkARyV2Bmxnk0AXbHUntJghb93396tXV/HNGzImAentWRbuhbc0W5F6intOrZ3LtX+EUARo7szBjuPrnpTtpBEkR2sKhYhCAMnPXHenOFB/esRu6LQBp21/cpJH8xbIOc1t2N3HPbERSASKejcVy0crx7TgYHQ96jYkXAkXIDEEDPSgDvJWNrHI8pDZHFYN/rAaPoTL6kdKp3uoy3DLEzbIcdqznlbJRxvBoACRJI7yOS/UU3c0inI2Z6+9MMqfaMrHgEYxTjDIFDucHOQKAGRoeGb7vqakZXAAbgdafu+6MZB7VG+/wAvc8mf9n0oAQyKwJcYHqKkwBy5BMgwo9Pen20Syo6jk46HtURVFYA/Ow7+lADQABtYcDvSMNiZJIB6Yppw5xkrzz71PNG8XDkE4yBQARsY1QD5iWGTRUMDfvVOcruooA6y4u/L3x4G7ccNWfqN3hVhD/O3X3qjNcK0rlyeScVX3szu7qOmKAGtK6uCg3DOClOecs4VsoB0xTEVoyHU89Vp5ThnYAOeooAIGHmP5mQMcD1psrrJgliuOMetNU7h1ODxz296AolbZjG3q9ACwBfNJfKnse1OAMsud2cHrS+aiyKj/MCOBSeW0chC48tuntQA2VS0jeXgBRkmnL5m9TnBIpREYSwYbsjrnpUW53IYngDAz3FAEkcqQ79+S+eGqx9uLLHhtpHf1qmrhnAIyFqaUxGIhV+YjJPpQB0UF01+ixMQsg4z7VIdHityXnYMN2V56VzEbzfIySbQo65rofDrvqEnkzsGVRuyT1oAuyhLVkzHuZxniqF/bqY2mnXjOAB2rWupoInIycKMgYrntT1Q3e0Wi+XH/H70AUJGRWaOPof0qGJypOV2beMjnNI6AnKyZZup9PamgusbIcKoPBoAto6yRgO+1R1PeofI3P8ALkMOhNSJAuRJNgxHkHNEt09yNkS/KvagC1pSqcvcNs288VeuNU01137DIyjHIrEO8fNGMgdfepfsyz+VKw8vIO4CgAkkidHxEoH8IzVdSVgJmiUk9CD0p7W65LAgqO+aYYvmTexRX4FAD4mj2qJFBBGN3cVHJFHu2hjs7H1q2bZIy27DADhqrKmQQ3Cfw0AJ5EmdxIKKMVGYzhdgKuO9WDBKVQq2ZOgpNl2N0bqGAPWgBsavHjcQGPPFJIqGTdncPWlmCPJhVKHHzYpFUJyRlR+tACZaKZmiPyt0FMMWZd0rnzB2qUZ/hXardTjpVm3sZpSWdtyHv3oAz87pB5jHK+lTb8so24x1HpV640W6t4BcLGTBn71N+ySvLErE5fqSMZoAqum9hkbR/eFQ5PmhIgCP7xrqxo4t7dyRjcOFNczcWhgujGr574oAaD5Uv3VJ7+1KjSPIxmXep6H0oCKwKuMMvX3pYpwsbRgH5+KAEchXRgeM0Tr/AMtCcZPCDpSyqWAyACPemRkFMOTgdTQA5pAikgbSR1pkYHBYHLelKxQPukGU7+9IJVVwEB39jigAzl3BHJ4FTrGSqAtuI65pg27mklOCvI9zUSsCxBPPUCgCWKFGnVgxA3DiilyzSKyfKpIFFADbiNV3Nuz8x4pABHyzbhjOPSpJ4wDuU4fcc1Gu3d9etACIwL7n4SpXQbgsZ+U81G5UO3y5QDIqQxRovm7/AJWHC0AMuP3bKCcjvjtREcuEyNpPT1FR7kxkck8YoVQ7At8vbNAEuyMl9rD5Dx7UiIcMzudo5pdiRhgW5PQ+tROzKFZsnHFAEiB5IWY8jtk9KDldol4XbjPqaAuYd5Gxs9PamqQWLum4AYA9T60AOSAuQUGAvemSEsyjkkH9KkjMgGwcFhnFLsdxt4BHU0ARyFAzYyB0xVvSVma9jEbGMgZBHcVUYbUOTlM5LYrb8IjdqvmcN8hAz6UAR65eCNgkJJfoz+tZO4g4PI6kiup1PRw/myIv7tjn3rBlhSBmcrgg8EnqKAKkyq6lovuUAoRsceZnofSmttedgDwecVJaxFy69D1oAd5b5RFyQ3b0qwkTROkcg/etU1qD5eV+V16k1GJWO7zjk9pPSgBkoEM8iQr8x7dhTXE+wHPHqKnib5VdmDbuKjll8tlihHfqaAI4VildI2co2cHirZhRXYufMjQ4WqswJudpG5h1NTQzIkgSKPcx5INAD5bZmXcTtVhkCovL8uH5+T0WpUE/mNufbuONvtQ7lUkVW+deAMUAVSksDAqeo55qVpHFvsK5zzmpVtwLQGRSZzyakiljaLyxFsccUAQKFa3+8EXu1VuYCSOnb3qy8D7GjRcqefxqFA7bBIuXU0ANnEhaNo25b7w9K2NLvkt5VWVBJ5ZweetZrQoZ2RDueTqvpVaVfssrKoO8dqAPUYFgltZcMptJMHZ6VT1WG2e3tRBCrInVq5jQdVRJRbyuSj9cnpXSST2s1uY438mWIjjruoAZqAItoy/zqRwO4rjNVVBe4VNrDnJr0G5sop4zcW0+6bAxHjiuG8SQzfaCZFxKOpFAGWsiytIA2GI5NIjo8CJ3UnnFJLCNq+X949aVsQy8HoKAAJE0xZyRkUgkxjyxuHcU5pEEpZeh6D1qvGD5mScFjwKAC4DO+F//AFUsbsCVA5x19KlDhAyKd3rTUZXdQo+U9qABANmX5XPfuaFAlmf5dh28e9Co8zi3Vc88mrl1DgRxEYK9+9AFdAnmxpG+WyMnFFbNjpYJEjn5eMcUUAZXEQl3DOScUzYHxKflx/FVvT4luHmj3fvOSmelV5BIssnmLuAGMCgCqX2h88E9T6ilkG7aF5UDOaseUswCxgrn+E1N9jWK1Jd8Pn7tAFFHC2v3OrY3U8BHXYT05+tRSZiIKr97j6U/aVkBZcgjGfegBnmZIBXJBpzsTnoQOQPenSQsiF5BhfY06OIOilBzQBGZT5WcfKeD7U5WKMDH8wIxSSH5DGoBwcmm5PmJg4Uc0AWYWWDPV2xn6GopBuOGc735CCnGSVndlA2EYzURc7FIHION3pQBI0qQIYSd7dx6GtXwyhnv41iOyQ8ZrHeUAksBuPfHWui8HW0X2nzZX2xqdxPpQBp+L5JNNaJOGbbyAetcdcXBucyMOOw9K0/FupJf6q3kEtHGcD6VkwyqZiJl2xkUAPiVAqnbnJ/On3T/AL4bF2KPvYpsP7qQYO8dF9qmkjVYsY3FuSaAJGnZ49qcAjpVYAkKGbYPSrKQvFb54O4ce1Q7Ukh9R3oAsRpsgkdhuf8AhNLKNkQZ1GeoohYCLynXEa9Dmop9zrvYlQvSgBBmfkfL60JGgRjkoFPJ9aSJWyWQ8e9Sz4KqJOcrnAoAgDlkLRkkA5zU8MgRt0jbixyDim70ZVAi2p93Oe9SvH+4VXxvDZFACtLI8hVZNw6njpUiOcvvUdODUCARzs7ttJpMKytJuLbe1AEkc6vHtGQ3pQ/7uEYXcx+8aRHYxLIiAs3aggOd7/KV7etADW8kZlT5An61G8YmbzQeO/vT5SBMGaPehHQetOhkMTqZIiobtQBWSOIvsjyHHP1rU0fUhLO0F0P3h4UniqU0Zdy0ZymeoFNlIMxeT5GjHBFAHoWnEiwmXZtl7Pmuc8YReXAgmG2Q87x3p3hrVXk/0a4kyO30qXxFi5VmbJhUcE9qAOLDyM+ScN2pA+UkQ8q38VI7FkwGwynk+1Eu6NVAIwe/WgBQQQEZeF6tSMxhYoV4bvT5I3VA5OM9qJNm1XJO7oPagBCDGBsGWP8AF61KyojDzBt4zx3qIK3lsu/c3b2pW4VEI+Ydc96AJ7OUJeI0x2R54NPnmSbVBMJMhTj8KqkgHefnP8PsaRPlcH+IckUAdPNO5QFJAYuDgUVhRTtujjIKqz8jNFACWoZLzCvgbiRWzbWjSRF0HVjkVz0jr5xXcY1DHBPrW1ot/IJtpcYb5Vz3NAEksZSMysQhj6ism7uxPK3lc5XvV3WZmMxRz35PrWMOHyRkg9vSgCUuBAq4+YnlvSmIdrjZJk5xz3qSV1KrgYamRgLIC4wRyT60AOGcn5uSehpfnVs5z2IprMoUlRkk8UittYq53DGSKAAopO5DhqVFwDhge5NGAELMPp9KVh93H3SM59KADBkQmNjtU9PWgAunK5X09DTrYSQIZeCudu6m3OwtlCd3XFACXIAVQwyccH0rVSd7LSiMcyfxVkxrtkBlUndyBVrUHV0SM5IA6elAFRCWIk2j396fgzcMoUZ4PpURyIt5+6OKCSir1G7pQBfihEMiOcNxgCoZPM81/LJKE4YelOjhdcOxO4c7SetSNLJ55eGPYr/eU0AKQwi2GXkdBTg6LiUx/KOCvqaYq+VKrunytxmljcJPMMA7ex70AEUSsjY+8eQM9KejFl3SAs68bagjXhnclVJ5OelWUmT5ii5RByfWgBrowkw43qewp0DrE7lOij7h5NVUlIIeJ8qT37U9kCsJVfMhPJ7UATyRrKFCHYXOcVOogR9jNulH8RPFVJyFkWTBaQrgAVGyme3DLGRj7xzQBPcEGTY7gA/dOM5qJo1ijxPLtbPGB1pfLbamDuA5FWSgdwXTdxnHpQAFdoQRMA3Ye1NhjDyuGB496j37pX3qR2X2qVQVUbhtx/Fn71ADVO5Mw/MVPNXSTKGVsF8Y+gqrbK6lvJA+Y/NntVpoipeRmwR6d6AIYnWBXhjGYz1PvVL95CJZAvmrnkHrWht2or4B3fdFU7iIybSgJkPVaABHaB4ryKPaSeldTfTR3nhqS4YhHxwK5AmaQbChVV7elalus114flFqCRGfmBoA59AqnLLlGPJoEcasRuLbuntV9bJ1dd0RIPWmzwLbykIPmP6UAUGc7NisQe9OBbOVHTqtTNAXKsUwynketLGu2TlCFoAjixjLrgn+LNNn2uxKj5DwD6mp2gDBRI2ASc1Hs37lzhI+QfWgCOJUWLnhu4oVdwJaQKfX2pfK/iL7h/OkETbCScHtQBLH9+Mu2cMOaKdB5UjqpPIIwfU0UARzMJLplKgjJzipIJWRg5ACRHKiozvWdkK7QSfmpkjt5gyORwPegC0zreOztkMe9Rm2EaoC+dxqW2lKzMW2ocdCKe0oaaPeAyA8kDpQBUEbRsxkIXHABqMSsrY4x15HWruoKTLk4KdRUEaebJhSAcZ6UARArkv9369zTctI5cjpUhiDsyswBx931p2x5ZY1VSoUbT70AQhCSW3df1pUcoQqth89D6Us4RJNr8YOMCnCM7g6EbhypPpQANlUdGyqk7se9OZhN5YYdOMCmtIW5OHbrgetEDM6P5q7B6+hoA0NOXz75Yo497qcYqLWN9teyJtCn+71xWt4dsTFGZycE8h6ztUjcXcxlYOWOQ3pQBnphYhJ971SlSASR+ZHIA3Ug9qmhh3w5VCv+160zygh4zuH60ATWZimIEpJkHfPWn3G0MZFB44HNVLYIZGkQESA8LVidysZaRcsegHagCVcPEsRPzEcA1AYVO0K5DA/NnvSRymW0YzKVcfxe1Ojl+UEYaI8Fu9AEgAR2hm+ZG7DtTJC1vJ+7xz2psGxg8WSrHncT2pnmQyybPmEa9Se9AEkBMbYG12J7dqknjEYOwbkflmHY1T3JHKDHnBNWdu9isb/ACg5IoAdDIcYZgzdBx0pxhcZPmDYOTiogyx3CkDOTgGrLJ5VyS5LAjPB70AMcOFV1OE7e9QyIJXBiZuD8wzUl6DIkby/u2xhFHcU2AlbaRTwQfvelAE7ToSqjGQNpqPDlTFK29FbIx1qO2eGM+YMuW6inqCLh2hyFPJB7UASMBO7bCY896vRRN5SRqCW6liagtVeMZCZVucmle7BYsqNxxxQBYjtVE6yeZvUDkZ6VEDHFMrE7X5wKYseZAFLKF569afKmZFkIyG6e1AFXz50ZixXcfatfwhGXvpQDmBhkpWPNDKJMvgYrX8K3EVrHOY1JmYED2oAvzvHCLyRwCFHyr6VxzXLFpDnkng4reXzorG+cfM79S3Irm2d1YoMYHPSgCRHkQMrH94eQfWoftJESrndITyfSnq26UiZgGx0pCpEhVwAPWgCwY8/62QMcDAFWSsYKszgIRyKoRFI5Q2SwHSljDTMVkUhs53dgKAJxCFkEqENHn7lDISobGDu+77VHCVklEbN8qnhh0NPDzMpOM7T8poAlhiX7Uryp8pIAx2opiS+W0atksWBNFADHjbzZDI4B3Hn0puI5GCEhD/eNbOsaHPGZJIlIjzWAwfdsdckUATqshl2qu8JyT7VCGCowGSrN0p0LSFSFyvvnrUbo3mDYenWgBzMys28knbgL7U2OQgYxtBHX+lSMpd1Yj5jxUT5XKqc4PSgB7Z8tWP3gfl9ameUCLbIf3nXIqvHl0IHGDnJp8R8thICH55BoAiKAAyE5Y8c0qEsmAD7mnuyF2bHB/SlWNsq4Q+X6+poAYNy58vDKeCfSrdrp8s8e+Ft7oc+X60lvB83mODt3cqK6nR0W0Vpdm1nb5B7UAUPD41NblsxEq3y7PQVHqtmiXLrKrMO4Hauzmu7M3MHlzokwXDY9a53xQzCUtcjEbdGXvQBzIj25SOT/dFNa3w6jnzmGWOeKkVQsyHOIyOtPkgleQqr/KP4qAKO0ElY1O4d6ElImwQWPU050MbARqVB4JPc0rO8coSJAz4+agBrSLJNlG4PbHFIZFPDqU9qfBExiLMVUjkLjmpbZoWdZMDf7jIoAhKt5w9GH5Utt1aM4z9KumAlRkctkjFQQp5hC7dgHUnvQBXkyrkbfnPftU0NsIiJHJLMO1XvszCIx7QQR96oDbSxIIgckc5NACyQKYxJBgMBjBpqQMy5L/N3GalWJoWDseGFRiIRlpwxaQnCj0FADGQb1MTb5BwAe1LHG6rKocZJyVPrUrFQQjrtmbncKW1iijuC21mbHPPU0AUxGzSmMAKTyatRhYAwdS8h6Y7VM1um0OyspJ5J7UiRCMsIDuGe/agBkc9xGSCMhe1WIX3DKQ5VvvVDCEa8Yg78D7tPjYluH8sE8igC6indCEXD45FSyxfJtCZY8g+lNjWPPmQFmJ75qeGFkk3I+AOuaAMmVyULuhLJxmoBeSIDsKq3cY5qfUo2iDP5o2HtVrwfZW96l3LdKcLyHPSgBGEsmkyvIrIMfnXNw/LIMDjtmu4u737bbfYoEXylyN4FcfcQGBxFIwyGOKAKrRqxLNksO1KiLPudQ3y9Tmh3khnbZg57GnbkP3VIfvg8UAPeNfILR5bb96lP7uNV80HP3cVGm4SAY69aR8Y+b73YUACL5ZPGT2+tPYvsCyN8+c8dhUfzFQSCGXkCljkKKz7NxPWgCS3H71H++GYAminW+0tGzKfmYD2ooA9V1yw81ZEQkBPmx61xWsaU8SGSLB8zg8fdru455LhHMnCg4Deoqe7s4J40REzkc0AePzWrRuIsMQOdw7mo0jAOEVhg5Oe1dvrOjYlk2ROFUZGK525sJWhYw8OeCp6mgDMlQOufmznhgeKaCVcRxASy9Tinm3niTIU/L95DWhoVk935hhXZL15FAGaS6qTLhMnGPemG3JXDZDHkL61u3Fn5StG6FnzliR0qMxiFUnRd7jjBoApW2lzS4DOPMYZCe1dJpmkvLaSRRriVBzupIoBEscqHdPJzj0rp9Nt7uaFlAUgr823g0AcvNpMlnYrdSYLZwRimW06NdQmBjIQPmH92u51uwE3h2OMERyIQTnvWZ4V06ArNvRAx6tigDkL23BnleJiGds5pJ5r1YFiuQHQfd3DNd3eaHAy8lQOqYHU1mXnh6dRHI7ZQjB9qAOSkjW6QqU5xkkVUjR8Hy2/dDjHeugu7NrOcxwkPGerCqaKolddnl46Z70AUHtUlTd82B19jWcI2RmAf5+xNdNC+ZVEKhn7ris7WYJVvNzoAH7AdKAKscOzazKfOPB9KtR2yb4yNpIHK4ptrKRISVyF4ya2ljjIRk2sQMHaKAMzZvl3RqSV4C+lTiOISIgT7v3q0Wspp1SG3Kq45Ygcmq8Vtm53SExt796AKcqxwzHBJJ6CpJJVMYc4Mg+XaKtyQpLKzXLrgdMCljsUBAjGVf5t3pQBTW3icru3dNxB9aijgYXA+Tar9j2rWjWMz+WwwgH3vemxQ7t6xZMu/gn0oApXFtAfncgPEcD3qCK0P2sStwMZAFX7uLMvmIMqvytn1p1vE7PvBBVeSKAKcsUWQ8jbd3IU1XuFkKsYQEfoCR1FbGpw73S4kVVUj5UxUO1pVRRtK45I7UAZKxCI4YAyHncKXychi7Bc+tSqhDSQvknPHrUdzAkcIaWT5z/DQBYs5EAIkU7F4GO9LeTvGriJT5feslfNEnlhsITxmti10t1WV7hjukxtz0oAxJoGmuYlYsUPJ9q0oituHiXeIJOPlrQtdGuY5ZiCJNo+8OgFGn6fNcXTW0OHce2aAM+0uIbR5EmYgHhFFQ6tZyxw+f5ZAk6Z7V6Pp/hWC1jgWaHz7l+XbGQtZPjnTZY7ENuAiHAAoA8zLMhyRlh1PanE7goPB6jFD/K+D0/umnW2YnIC8v03fw0ABXcfMdtpHGKcyK4GEOe5qPeHEmSCwPPoaVpEAx82cc+1ADJcLhQSQe9WbaNQ0WWBBPI9qrOdzBW+/1GOmKdG+xiQcjHT0oAuTMzzgsu0IfkUd6KqLLJJLHz/EOvpRQB6Tol41wWMjLsUn5RXRwy7oMLx6GvMdOnaK7/dSYdTnaTwa7awvmkMccpUSMeR6CgDWut1zCFyoZevuKoXGmW9wo8xfKlHRhwDWhGn2ncpIROmR3qxa2m0Hcd4HAzQByUuiI0r7RuyOtQ2OmNa3HnJE/wAvUjpXbbAW2xqGPfHapHjYERJHmM8saAOVuNDiubmORpPLWUZOajfQWkmCKgKqdowOtdW9ms42MyoUOVB70mGDFowUnUYAPSgDjzpdxpl0fNhZj1UY7Vbtbi7lt5pI1e3dTtANdbLK0luIp9j3OM7sdKypbRygWMgoTl2PagB+qiRNCtxcxszSL98dKy/D8bC4J3YjHylT1rSvNWt00p7BZRLPnEbHoKz9JP2yQWtxNHHdL/d4zQBuhfPZtgAWI8bhTZw9woglYKX5/Cm6d9qWeWCSI4AwJOxpAsnmFZAPNHC0AY97YqLgxLgRryWPesPVo45I8hNoU4B9TXazzAw+XLbsSONwFY9/YJbupb94r/Mo9KAOSsXe0uMzRhVx94jpUNxPbPdl3Ys3YnpiuvNpFb27yXBWYSclB1FYtzpljMBISIY+iqx5oApF7QxlVZF3kHJqVbm0iUm3dDJ3HpVDVtJs7aH99chsn5dhrvvAPgzw1q2ltPc3TJcgYA3daAOI/tdLcl4jnHGRU9lqcNxMHkdEVf71XvFOjWWhSzQqpnAPy7ad4X8Lw+IJ0heCREk6Y7UAUmmWeQpbmNucA44NWYIrkjKxEbR82OmK9HX4e+G7WNIbu5ktnUc5bFc/rXgS3uRNL4S1wTPGcNAzEk0AcnJO8kDyrCPIjbaxFPj8lyj3DFYgPlZDiorzwf4utbRkeBxDIctgdadpvgbW5YRJq8osrGP/AJ6cFhQBZ2RxW8jiVPLbkBupNYt5LBHEhUyeexztSvRfD+jeCZmhtLme6lnY43B/lFM+I/he18KXdpe+H5YbyKQYaNvmK0Aeb3uq3Lxxq9q+8cKSOMU03GoCHLWjiIdcDk11N2pvXjluLcoqkZ2itq2tZXxLHEGt/wCFW6mgDz6O/mWQE2bopGNzjpVcQCcFpDlwePavUNTklitkLWMLj+JQvIrli0F1qMkZt9sLDnaPu0AYsEVnGVBIeRvyFbUQwgcMJE7L1q5ZeHbNyiw5dD371YjsHspnjaBgoGFJFAGbHdTvLNFHE6Wpxvaui0RntpCVthGvGJCOTWfY6Vcl5FViQTuIrc0pHubpBchlMfATsaANuWdYNhyMTda5/wAZ2sdzFGoyowTz0qv4s142cu2CMNIn3VxmuYuJ9d8QRr5qeSF68Y4oA5HUY9kmPLy6sQGHQ1DLbyzXCLtKjvXSXWjSxXIDsCq449667TfD6jyZZNnzDJBFAHl02lSp8uxh3FVvskruAEIYeo617bJ4fFxKr2gUseCG6VSk8MqJ3jeEtIOdy0AeRy287rtkiwV53KMU9bWVJA0Ue4kcDH869ObwsjS7VEhB61JYeFzbMzbc8457UAcR4Y8NzX94EuRtZzwMdKK9f0K1h08qXjBdzgMR0ooA8B+0EX21+MtwRXUaZqBaJt2Mr/F3NcoQEmZm+cEnkdqnhvFgO6POCejdqAPV9EuEuI4nGQo7Hua2JFlWV0LKG27lFebaLfSfKPMyG7J2rtYdSE0ajlpVGCe+KANqI5t9qlRIfvEUxzJGphEoL4zkUzSZld2ijU4Yc7utXrxLe2VXu1MMI4LnqaAM8XHnlWkTMsfAC1cEbrIL3ymYgYK1i3vimxt5XTTVUxgf6xh1NZN141v5MsiKDENwUD71AHXeRAHSe5kW3hkb5g55rj9f8Qvc6jLY6Sn+jxnazD+L3rmptXvdcmY6hKwXO5UTtV6zhlkAe2UK+doI70AWLu4S0slhhjVpJDlmI+YVNpH9n2ztOyXLXBGDJ2FXLbSrPTnS51KRnnJ+ZM8CrOtahb2Wj3DxpFtkPy4HOKANSKWH+zhvuWfcNw2HkU5Z8WiOqkEDAZ+9cJ4Pvnm1VU6wAciu5u1XyiTHIVByqigCe2a5nQq5QD9TVmWyAiH2mFwrDh8VRtI55HEsYPThT2qTVPEyabDHDqALZGCPSgDlNau49OaSOzYPMfu7+RXOHS5JYftmoSSSOwJEcR6Vfmkjv9Za5VdtuoO3Peo73UWERERUMv8ADQBgmKJVCzLKFPTzO1aOi6o9tctFCXWI9GqC4mEqRu4EnYqO1XJNHku4A1uyxx9fcUAN1O/WOVnmlaRn5AJ6VBYeNdT0udZbJlUqcrnpWTfwSm4WJvnYHG4Ulzpc8MgRwDjrQB2t949k8TXMI1bEE/Csy8A45zXpnw4vdGTU2tYBGLuRC4YfxV853cJik29W7mvXfgzrei28QW+gkbU1fEcwHCr70AezXkqJNsllYR9WVz0ryjxhqFtqt5cfaLx1s7Q7dgbrXpeu6d/b0MksF9brsTzHYH07V8w+LbuWfULmFJFWFHIYj+OgDWufFdpExjsbdQobCyAc1kalrt1qEjfvZRsPGDxWKBCFQkEc8D1rWj0x1sZboA4JoA09M8RalC0UKKJs9cjPFX9V8UXXzQ2gdZx90L0FcZEbiOXIdomb+I9qnh1CUFgNrFDy/c0AXrjXNXbLtLKbjPKk8Yrf8O6gWdbllxJ0cP0NYMN8l46JHHyPvHua0B5L3IjRirY6CgDu8o+x4Ds74WrUatdzCOa43biAMHpXmyy6hZRS3UUjMUONpPatrwZqCNPI7SkzucgOelAHrUGnmztHFwUEa4O/vXO6vqCzXoitIz5ajAlXvV6O9mnXbchmhk4bHap73RBplmjWsiS2k38Z/gJoA5z+zYrZHutQQvIeUB6k1l7ru5JJmSHOfkHBxXTaxpUttYrB/aNvcXjfNGM5xXD61HqOlXcN7eQOIX4LAfLQBqaVp7zjy5W3u7YDelb80LoRDESwGBkVkaPcwsYXhkO3r+dbMd3FHC+7OM5U+tAG+LVjHAGYxBRncO9Pmtzbsm2Tc7fmagtrsi1jDHeD1z2q5cz28VrHcfeYnr6UAQyhooSy7BK3GD2qrK8y4QmPaBktVOfXrRJs/f8AU9hU8Oo2l7GFidS2elAFxRmNJHKFc/KBRUsTAOIZIthwCpPeigD5lfau5QcEseaR12nkqy47VJdRCG6lVuYxzz1pYYxGAGBCtyvvQBY0+TywUZjG3VcV2sJlhit2U4dgMn1rjWwX+cKy4G3HXNdlo9wGiSW6U+XGuAKALMmtSWZd4+GAxuPTNY2peJbq5kH2yU3CbfljXkA1n6zePqE0qwMEjJwqDqa29G8Pxx2sVxfYgixgl+KAMSztZpphPPtjtwd232rY03Sf7SupLy6l8iyA2AA4yK3dPk0m9WRbWN5o4T87YyCKZqeqoYxBZ26NG3yKuOhoAoadY2sty0WlxtJGp+d29K2ra3stIkmmkkbzcFkRuma0dLs10u3iDKF3rvcr0z6VzGt61BdXzmSNQU4UeooAq6reSSRtNdcmQ547Vk3Gn3utRRpCGWEHHzVc0po7y6kR5A4dsKh/hrrbfUYbMJYRRoSpyzUAVNB8OrolsBId0rkMCK6eMr5LSTSAFRhVzTJ/9LthKsi8EAKDzRDGoLLcIc7DtPagDPsbgxW93N5jFUPODXC6zqsuuXqh0CQKcbmHWunwlvYXwlkxvbgetc3Yac1zdxxTEKpGQq0AW1itYLFxMxK/wbetYcdvLcHdgRjrvbuK3NbjhsYyEZWYDkN2rFuLv7Ta2zqxGBtIXpQBPNBZNaiSLepU4Zh0qOBpS8sdtKRHj5dx61WNxPCWg2RtB1xTtPHmXCeeSqt029vrQAsNsgAl80GQH5gT0qcyW5EjeY7SjpnoauQ2cc3mwqNuOQx70XFgrRoWTapBC7e9AHKaiwnfcAAw/I1NoOpSaNfpcMQUZsOo9PakvNOuA0gCMVXnjtWYZPNIUjDKMc0AfQFlpdrqejm8t766gtmXzZFVsEj0rxbxBJa3WoTG3G2FXwgbqfrXc+EPF9rZeDb6xviRdFSkXpXmLgszMWBkyeO1AE0EZS4UvtkbcMJ6CuzngU2SRwOQhG5wegNczoq745GZQXH8Xet7TYLlrNygLyMclfQUAYuoAh1MKiYdCo7U+KHT7iIQIkkN0vJLcA1urZBpMqqxt9O9W7fTUnXy5FjLKPmcdaAOLvori2kVowFHbb3+taug3ke8PKgD9C7VqX2lNYKDLbzzwSDggZKiuav4Fiwbdz5AOTnrQB3q2cUkDu5whHA9a5u9sriwmEsERSM87sVteG9TS8228skW6MfJz1+tbl1avfWr+eU54Cr2oA3PAd0b/Sw1wN+0Yx610txAbjSLqztjtLDKq3r7V5f4TupNJv5bHfiN+7dq9Is/MW1EisXQf8tB2oA8k1Xw74oMn2i3imkljJI29hWx4V8ZSt52j+N7XbaEbYmkXlTXc2HiBI5njjuSGBw2TWX44ttH1GONHCObjjzB/CaAOQ1IxaLqUbWwMtnMflK8gCtGyeK6VvImXeOQjmtSPT/sPgmS1voozHFzFcN1I+tV9F0vSdQtbeWOZhcA4byz/OgBkWsvZiSK6jYkjGVHApl5re5fs1uTsxkhq1bjw1d+ZJHEN8cg4keqN3oupW0EojtEkVRjzAM5oA52bVLWNmSRDsYYJFZ2o2TSYbSLuSI4z1xmtC9vLa3uoYL+wdAvLtt611Gl2GjahCpsRJknigDnNC8bajb3VvZ6ym5UIXzCOcUVL490T7O0E8WflYBjRQBzWraYkszlVO4jGSOK56eKeOMqVYyJ0z0A9q9IuLSaZiPLHlqeSK5zVbQtE45yPSgDC06WPZmQLkfxH1q487Xe6GCVgMc7TxVWEQwK6ToTtGQvrS2MxieV9iqGH3fagDpvC2jWlnbfadRfdIGypJ60uuXs3iXULfTxmCFWGQOMrWPC883NzLthx+7UHvW54KIn8VRtc7WKLhR7UAeh6fpmn6ZZHSNOjCvNDjeRyWNUNM0YaM3lPEss27JZ+cUWt6Br19dzHAtlLIp6EjtXK+LPFVzqs3nTb7LC5Xy+N1AGt401yIRiyhdV3H5iOorzvVGYy4IIUDhz3p8RS7VZZJHd938RqlqkzT3ISJwVj6igBui3b6fNLORuk6Cra39x9qSWR8yOc4B61jk4UmTKqxxtHWnwxjzo/KMhYHC5oA9f8DZv0lmlJG0421o3xdbW8PmYZflTNR/Cawe7hlySWDDcoqT4h/6LrVvbKoWMsMgdTQBzWsRyDS7aGQIjyrvLN1zVbT4ZZoAixOksfHm+orT8Vx/aJ4I3U4AwpXsKhg1KTTHitoY2uIsYYkUAcz4wt/s0QaR8+YOTmszwlEb2UwTFUhToxrpvE9j/AGmn7lXAVSeelY3gh7drs2V4p5yQVHpQBevLW2tYpiWDOvX3rDWd7vEVoAjDpnvW7rVjI80htkcWpOCx7VPpPhp4Gjlb54n+460AZQuLm2gU3QAc9WXoK0dO1b7WYrN4yeDh1HSuivvDsn2C5by96IMkEc1wBjvNOf7baA+WpIKt2oAZIby11SXEjtAG+YH0qprNpGjLdQKfJYZNaZlk1CHejKJG6qKum3R9OETK+9V+YEcUAcgNpUsFZgRxntUcSERMSC2fTtXTXVusenK1oikkYOaj0mydbCTzIRl37daAIND06aRPMDFUHPNdxpL20KbiWEp4OOlYEqSR+Xb2yuQRyBVmx1OWxm8iaOEseBv60AdMunxG4ElwwS3/AIfU1cbS4YQ09urOwP3U71mJfTWFq1xdxx3IblU6haw9Q8VTm7gOnSqnmjDoD0oA6mG2vL65aWS4WGMDiFj1Fcj4w0lpCZ4IDFaJxIegJro9O0a9v42uDcMDjhia1IfDU93prWt5ds0JBZ1z6UAeOWsE1ttntwSqnJI7V6H4X183se0+UMDqeprE1C1isFuY7Pebfplq5nSpzYXyKzfu1cE+9AHoHiIBGhv449uG+cetdlZ6tBLoEjxl1jROi9CcVh3qpq2mvPt2wYAUCsqIy2kE1nbSKEdc4c+3agDnrrVvLuncq6u5OBVL+03Z4CZnHz/cY1jTTS/aXedyxRiAfxpJEaWfzRkmP5hQB6N4uvLnU9JtrWC4KxQruZM8NXI6Bq1xpkrGNxgnHB6VdlmlvdFt7y3BM0PEyL6VkaisE3kyWuUJ6jtmgD2Hwl42iuythfOyt/CT3r0WKVUEagHy26ehr5gtb0syo52Sxn5X6V7t8OfEUWpaaljcnfKn8R64oAg+KWkJeaM06RBJF53KOtc18Mf3NszS4ITsK9Zu0W7sXtWVXjbI2nrXjniXw7e+F7p7/S5pGic48lqAOh8QtHIJ1aN5ImGemcGisu28XvFpQ862jadwAykcqKKAIIrry1lijVmkYnBPSqFzYMbWfO3zSM1sRSYRSUXczECojD5sjBjsX+ImgDzzUYPtERhCbJx0b1rDdJYZR5jHPSu81WySW5k2Nyg4xXGX0cxvSX2gjoe1ADoLovGcZIXoretdh8O7dZp7m9lYIUTBPpXnxmYqYgP327gr3r07whbpZWP2W5KoLiPJJOOTQBT8TatlfJhGGdvvr1IrnNZWfyI0mO6XHyhuwrqGgs9Pm8tCLm5L8Buij1rnPEzfab4ByQ4OMr0xQBmGdvLAwFdRhttVo4dzt5LAYG5mPUmnDbbTuNxdGGD60WsDyuQoJGeo9KAEhjM8hkKlmxgDFamk27XN4qYCsi8j3qB4hpw3mTJJ+UL2rb321lZw3WR9pnxkd6APaPhVpMttbGSMMsxXzDxwRXO+LQt54q84EySd17LXpPw4kdfDcd03+rS2OWP0rzvSZIrzUdSuwMoHIU0Acbq8lzOt0wdh5Eg6elXtLmW+s1VAFLkYYdaytcuf7O1mScbmtWysiHpmtbwxF5EiS3ARLa4+eL0oAtXFpdWtjeQ3m0Dadjj6V5n4blFvraI+fO3cHtjNe530R1OwNu6ovIBavNvGWhiwcR2axqyrkzZwaALmqTLKLlI5SYgh3Kvriut8AwfbPCFoqLuCOSS3XGa8ks9baHThaQRiWdzh3PU1798K9Ie20S1eck71OUHvQAgIF/dMF3xsMBO3Sub8X+HI7e0t9T2f6FcErJGo+7XUXdtMPElzBa/IsYJwa2I4U1nwuLFFUyZJYN7elAHz/rfh6XRbvzrL5rUfOD7GtPRU8+JptQCxxuvy4712uv6VLBp0yzITCFxuA6CuInAGnhImMmwfKKAKMVrEfOVsrCJPlbFTXTvb25kt03tuwOOKsG0MWjLcSSAyOcmI9qs+H7EXjMbifZbYJ2Z6UAR29jOltGtsGmvrtwNwGQma1rr4X3VtqUVveSmS4mXzN392vVtC8Lpa+EIruwWNp9yyqW7qKyNTvbjxR4ptbi1fyEsUMc4U9TQBxFv4Lu57j7OkjmOMYfPekk+GunTQu1tK8dxGcMT2r2GyhWJDIw2hu/rVAWkMGpTTD54pT900AeOT2dxobLYpetJD13E9K2ItViEEKJcK8rDB2msr4qWF3b60TDHtgkB4HrXBQ2OqxQh0whB5IPK0AdL4lkKu8ICLHGM8/wAVeevi7ut6KVctgDtW3qcV9cDZNIWk4wQetdH4Q0WOWMNfWxWRT97bQAXF7LpHhxYbuba0oyg9Kgtb0XkFjcSqNoyCw/ipfiZsuGit4UTYuAvrXRafpESeF9Pg8tQYVLSNjnkUAeb61a+VKzYARzkAVTgn8ohkRmQ8NxXTeI7aMaZbXVuS8bMQ/HTFYVuPMJWMhI1GRnvQBb0LV10fUfOkRms5eJUIqXVjaPG09kuIiSQp7ZrPiR73KgKSh5Wr15CWk2xICu0ArQBiNuS1b5tx6g11Pw51p7DXrZZHO2Q4Jz0rn2hkP7uIKfYnpRAfs1zG8WMoeT70AfUlxvNmmoW0gZVPO01yeu3NxqFmRPGw5JWQDj8a5Dwb42ka3aKcssURyV7NXpF1q8A0GK4iiR7e5ym09jQB4jPdvaao27DjOGz3oqDU/Mh1K53xjyi2VY9uaKAOvW5gkKgSOu1yeO1QXOqRxholczbvWuettVR5yxRo0I2kkdarG4kW6CRRAx7s7x2oA076Urhotwc8Edq5/UoXIdZumMgmrs2pN5zKCCo4B96h1LE5jhmZhKwBXHegDH0WyaXVIAx2x7+feuv8aSSI9rEjKhXGwA9adp2mW+lX9jc3h3dCyeg9ax/HV5Df62bmDcsCH5SOlAE17cZt0JBS46O69cVm3N7EbcqCTL0Vj3qs8kssLyJIWJGMGkFqy+WF8t5CucE8CgCB03Rq3Pneg/iPpXQvYS6NZQ3ExIlmG4xegqx4P05ZtRF3eIDZ2p3u3YsO1ZXiLWZNa8Sz3W7ZbLlI0HZaAKkgZrhpgQ4IyqntWv4d06fxDr+nQSpgRsCwHcVjW8El3fJBbrJvc7VKivpD4EeD7e0klv7keZcRKEO4dGoA6fxHKvhf4c3MYXZJOvlRBevzDFcHHZjw/wCCbZ5VDPIu+Rh1H1roviVNPr3jTTNH0yVZIIF33CA8KQa5345TJpfhqK2glKNKR8vqKAPJNfvXvFneP95bueT3FdFoLSL4bto7xC9qCNkv92uNgOyDY+Y4SMfUmvU/hVbSS6Be6VqKCaF23RhuuPagC1qdt5emR3ltqEbIowVD15Lrd1qOrXstrb+ZcOWARY/mr0/WPh3FLZ3U8V/cW8EcgDRDoaueHPD0HhK+i1TS188Mn/LYY5oA53wj4Aj8PWp1nxK6pKMFLY9T9RXqfgvX7PUbhIYGELKRhRXmHjC7v7q8a41OTzHlyQgPC1s/B6GCTXYppHDKOTQB6xqCL/bt3cmNXURksV69KxPC8ypLZagQTExcGP1rqbRIvO167j3FGG0LjgcdqxtNtY/sNoEOxVLYx6mgCvrcXm2F0JRtgZT8p7CvELyOOxvwXk8uA/dx3r2vxNLKLeXTwC8ki7dw6jNeEeIYZbPWobC52zBTxk8igDoQbUWzT3KKyFcA9xWLopjmuJhEzFWO3HoK0rmBYdIuCQWOOB2Bqf4Z6WL9kiZDHIzZZmGMigD2PwWNQsPAlyJHWeCNSYiTyBjpXJ/Du2kuL68uEJVZZN0gNeo6PYiPw1cWgG1cMBjvx1rgvh0k8MN7OwDSRylWT8aAOtuYkmDRO3lxqMJ71l3rRWNjF5rgyqe5rXaPzn8xsMo52jtWP4yggudOMqLwVxkdjQBm+JtEm8SacrWyRrNjKuTxXkj3B0W6m07X7NoomODOq/Kfxrq/CvjC40C5fTNYYzWjttjfqV5r0DVdK07W9M8q4CXkD8gdSKAPIcWJSOWxhimt16yMeRVW/wBVWKeSCxm3yMMBQeBXX6j8NbM+YLDULi1tz/yxUcGqlx4GsPDumT6ldSl5tuFHUmgDyLUYZp9ZhgmdpJC4J745r0Hx1O+maPZzwsUV0CuvTtiuG0syt4ijZgQrv8rfjXsXxC8OzS+GNPu7iANAgAf8aAPFtPv1Ec9nOxa1m5j56Gss27W025stECdorY1vRDp16kY2qkgzDms2IySo8DsVkj6bujUAJYDzp0kikELMcNg9BU0s7Wd9GRIXQnDe9VUgeV2RFCSmnCORYW85QGXpmgB08ht75ZRhkc9K1r/RE1CKO80liccyx9x+Fc5IzKqqzDOc7geRWtpOoSWLRyW8gVs/Nzw1AEFrdKLopGXVRwwYYr1jwQq6x4Oug9wfMt2LIpNec60lne2y3fEFyxxtXoT61e8KavLpVtNbRrvWQfMwoAdqSSec0N3yjHHFFS6zewtJFHGRIow28c4NFAGjqXheS/0yW+RvKgiO7aOprCQOujCO3RzNIxQBhya9buYLSzljJlLWcmf3bdzXl+tax5GstexISkTkRxAcDFAGJZWjnVIIJ4JUJb5sqQK2fsovfFUS26bre2+8+OBius0TWYtftWkkjiF0oyF4zWRfWNz4W0e4F83lTXkhYZ6lTQBiX80WoeK/s0c52Snygx6LXSa1oVhbXdppMTRzSEA5z1avOr+0mjkW5hIGfu885rY8K3fm3sTTyMb1T8pagCzf6NLY3c1sbQFhycdAKp6boM09w5VSWYYCjsKut4g1B9feznK7pZNrSf7Neg6de2s0ss2mwIkVlFiWU/xEUAcP4ghk0vSI7GCZo4mw8o9T6VzFkLctuMW4n5ce1XNYurzV9Rnmfi23E5PpVONJLi5S0sU3Hsw9aAOj8Ma9baZqhaSGPbGML65r6E8CXMuieBNQ1e4GXuXM0YPuOK8U8F/D95btb2+jZmicFkPRq94vLZp/h/LBMnlK0gWNB/CO1AGF8MNPa5gvtWmQHUppSzuf7vfFeT/HvUl1HxHAiO2y3GzA9a94Fv8A2X4ctrSwOJvL+ZhXzh8QbORdceV2LMSdwNAGJayJI8SXR3KCCma9m8Co7xiW3KtckbQqnpXi1nGZm3MuURulereBrk2LxS2oYNLyc9qAOvvjdXn/ABKpTsmVt8jD2rmvEFxdN5kPnhYYiAnPWvUU0q1ubCS6hkP2h1+Yn1rw3xva6tbTvFeQrDAMlHB5YUAZepXTXHmSIRIUUhh6Vc+FmpPp00808YMAPG081zVjf/8AEquBbQkzSMFJ9a9V+EHhXYFFxELhX+dlP8JoA9e8OTSXukRzJBtjmU7wwwTWVdwfZtiQ/eDEhe1dZAkq26RqqxRAYPbaK5XU5jeC7i00b0i+/cN0HrigCrpiH+3VuJgsql/mB5xxXi3xDks1+KZWyTO9uh6A17ho2iyNZSzvO6xgEh/XivnK/hmvfFl3+8I2T5WY9SKAOg8RTCDTLu3P+tJyCOgNd/8ADLTnk8NWl5ebFdRhcHrXm9zA0mn3iy7ni/56Y53V2vgbU0b4d3EW9jcW54I6igD2zRZvOsOVAUEqAO4rlbLT10zxPfRKdkE/zjHrWZ8M/FMt1YSLKjvGmSWI711F2P7R0mTUbeMm6j+YL647UAV/szWrRknYsvJ96r+Int4bKUDHHVD0NbGnTx6xpRndP3jglUI+4RXgPjbxje2OsXNrKobySVY0Acn42n2alNKsoRFbKgGtrwH4v1OK6jFsUcYwQTXn+p30WrXPlyLtRjuyK6DwPpMLahHdJeGJkPMfrQB9A6TcC+mHnkkgZOexqp47s0t9AMtw26abhAegqnqPiGx06wWWzAklK4b2Nefah4i1LVJXj1CVjFu/dLQBzNxpEsOo25WQlPMU7h9a9v8AivdlfCOl2sUzbZYwcDvgVyWlaA106LscqCpwBXWeK7BLiW2EJMkNmmGz2yKAPAfEd3JrcUUnl4ez4461RsTbara+Q7GO+j+5njcal8Vu2ma9ctbsVVz93HFULWVJ7mORlWOUEEMOtAD47ZriYWk7tBfIflboGq/e6ZcfZS90h85eCOxFaniCO1vLOO9hf95Go3OvUGrXhvUW1COHTdQClZflWf0oA4CWwZnfyQSxH3aihiIZCylQDgoe1dz4o0G+0aMPEg8oMStwOhrkWjuZWy4Vm6kk9aAG3ETJu3SZjxkDPSpINRNqmyA7Bj5i3eiXYrhpUIK9FHevVvDPw68JxWNvqfinWmAuOY7dex9KAPLNPjnur9UtA+2QjO4cGivU9f8AFfh53ex0PTEgjt/lWbHLY70UAaXieyOn/wBmPrE/ls8pKxoc4HvXmfjLULY6ljTQNm7lq6H4ialMt/sAaaQscbuij2rzrYBcHfmPklvegDV8I3Bi8R2IRsCSUBjmu8+NE327xnYW945KrCoVR0+tea6TE0mr6f8AZ1AYz4UZ967z4x2s1n4jtpZywuI7VGAx1oA43xBayR6qI/MIiRMgiq+jqj6pHM8zKqt8x9q1taga70+3vYmwCo3gdaw0OIxKoyoPSgC1qCxR6uZoJHMRfOccmtzSNRk+w30Fs7mJgS2RjNc1NcvLJHIFA29BWhDLLFpVw8bbWlJzx2oAgN3JJEVBxGBt2it3wTeWel3XmzkHbyM+vpXKBpC6+WfLATv/ABGrdlGskQG0b1bJOaAPpz4X66viM3O2BYxEpAI716Hqdt9p0tLOLAlYBsfTvXmv7PFi1votzNImHkl4/wB3FeoxZl1W4mHIhTywPU9aAOZsbhFu5bcoXESENn1rxr4lWjy3bzyQDazYAHXFe4TtHYa1awSqQ9+SMqMgH0rzb4uS2UPimysYZMThBvX60AeV6bpoCSM6lIQ2c11ljqMcItZAfLVHVAQOGp3iu1NposqxqoWT5hnjIry6PX528u2bGyNtwz2xQB9Yajex6XpgmjO4SpuI9DivOPGXn+JdFhhiw1y7hR22g1w2seOLq90KKITkSgY+lWfhR4gvLjVfstwPNk3YQ0AbuteG7HQF0/SreXzLrZukPvXqHgHytJ8PPfvzM45Hasjx3pVrp2qaZeXcYZ5VIkf0NdFClvq3gOaHRwF8r73vjk0ATR+IxqtrI9w/2ay6MyjkisTWPF+i2NilpbkrZKfmCDJc+9WdJtI9R0a3soYF+zSKyhycHNeY6tpDaBqNxY36jcW3RuTwKAPVLXxRczaOwWzSO3eMrHzyARXjMZtba/ulmQzSFzgY6Vur4shhRLItunICg44qZ9PLDZbQK9048x5BzxQBmRgzqbJQVjlG847VhaXqb+GZ72xQG4M5OARwK6yFkjmjXPlMy4YEda5HxLMkGrxwW6jzHHBoA3LK91vT7MbdttazjIK16h8O9YuMKJ2Z7dI9srf7XrXi3najFcw29xIbmLbwvZa9H8ALPLbzQGWS3LHP3eG9s0AdrpsE9pqGtak1yRYXB3RL/dGOa+aPiFdw3Xia7+yS+ajMd5r2D4j+Mk0zw7c6cGWG9Q7Bg8sDXzezlpHO9leQ5Y0AWIAsMqRwwiWRjwD2Fbb3UGlJ5q4Nyw6Z4FXfDnhbVbrQbzVhbbIrYYEzcVxvnLOrpINz7sljQB2nha/ubu6e2vPlWbnd1xWwcPrkULyBYrY4z/erhNKvPse6Xzsgj5U9K6GC4W606C434dclvegD6X8IT2VjDaQySbrrUVJTvjAqjr9ncWnhLW8fNcRNuLD0zmvF/AnjW4XxvpK3J/0eMlFB96+hSo1a28QWQO1JF4f6rQB8s+Im07Xr4mN/JuFABX1Nc7qGiXenN5uxZFH8SnPFLriz2mqXCLHmaORgGz71Xt7q9X5TcsGHLo3egAsXlkinjinCRt95GNXLWOSxubcCbdGTwM9Kx5/LkZw6lcntVtLlYzGhjLhf4vSgD13VPE6Hw1aabf2im05IfHJNeW+Jrm1mvFWxBjHQAVtzXsdzowia6Msg+4hH3a5G4YtNsYKueA/oaAJtNnkhn8+4i88J0U1t2aXvijxHYWtmhCI25sHhR71iNI0FskcS5LnAbuTXdWt2ngbQWitxnWL1MtIeqKaAOd8RQImrTQWso3o21yOmQaKoaRsmvXMjFg7bnc+tFAHZ+J7wEPHcQh5dx2yHjFcHcHeztNjd2A7177410C3ntXU26AcneDzXi2saLbW/P2llYNwCKALPw1k0my1yG811nVIG8yLjjNdZ8ZNb0/xM9vqWmXPmuD5b8YworzeVriKNbe4AYE5DegrQ0axivLK+MMhAiTLKT1oAz7a5mju2RXMkLrgIelLPIougqqEiA+ZfSmRB4nhlwCM7fpSTxNLds8KmQMcMoFABexorxvGcoPmxV4mSOwQvFtimbGay7osJvK8spxhfauw1e0mtvCGn3Uo4WQAjFAHLNHFg+fuKI2FOO9WLbyisoVjGMZzSz3kdxGAkYA3Z+tXPD0EF/qUMUykqJAXGO1AH018CYp/+EKW4nDAtwmR1A713aSRWUayg/u3YB89Q3rXn/wALPFS61rM+l2KLHp+nxbFVe5ra8deIbeCGS1jcF4hvbHqKALuoSWmlXJluboO0twsqFufLHoK8a+JclrP4nu9QQ+ZOzAROeABjiuR1XxpqGraodzbrZJgdpbHFL8StXbULuyNoBHCIcbQepoAi8Za5Lc2tpBcOPOSPGFPWvPzEJCd64f8AvCtS48wwRyyRFiExnrVL/lyEiMd2cFSOlADILQhsCQkHrXa/DK9i0vxDbSSP5UImVWz35rkGnxbDy49uOAa2/B9r9v1qzW5H7hZlct64NAH1l8RbG11HwncyzsEESiVJO4rl/hbKsTRiOZjaXaN+7cY5FdZ4vs21TwqI7Ybl+RiucZUdq8l1DXptG1cS3UP2O1t8CMdiO9AHqq6R9kItYDtclmiCnhcmuI+JXhKdtEN3c3QuL1DnbntVD/hd2nSarbWmj2fnyykLLOc/LXqN/Z2c9gNSulMzeUGPPBBoA+SdWv5LLc5h3OBxnsa6bw147gi0yKG4lMF052s2M8VkfFJkbxFdxadEqwdgDXnIwJMTE5Bxg8UAe5eINfskiW6zHOsS8MG5JryvUtdm1HU0vB8mOBjtWRJJhfLErFc5CE8Glgz9pVSAkbHJFAHo2j6/ClmxnbExYDea9e8GeJtMj0Kb+0buKMINytkZJr55mjWexmeCPiI9utL4Hgh1LxLaRamXmtpGCiPJFAHuPh7wpo/j7WLnUNRld+cxdtwq5rPwnsdMnN7Bbi7tt43p3UetNsbhfBnimKyuAkcDYEChuxr1268+TTlNmUWRxuw3OR3oA8S+Lutw6R4WGgaEV+yMB5hA5HtXg88VutrG/Cv7d69J+MCAazsiUwiQ5kBry9rV5rh0jOY179qAKk8OxlKnhujelekW/h9LX4cz6skyyMuMDPTNcDfeWY/JjQ4jHLetddYcfDG5ZJn++PkbvQBiWN3HY/YbxgTc7un93NfSvwr1ZrvS9XiuJxJcBAwY+m2vlrTf3l45uSQnBxivTfBfimHQTcKWMkV6Ain07UAc34wgEmsz4YRyb2x/tHNchKky3AS6T526MeBXW/EmBra6t23EI537/rVRkjuLG2TV42FuR8twB0oA52VmgUhog3mcYHOPepEu0jj8tIvmx96rE0Qhc/ZwDtPyk9xRBbNNOIkUburGgCgJwi+Yq/MxwT6VExUQybhlhz9K07nSbmNmS2h88dTjtWXNEQmVLeZnDqR0oAWGeTfC0fzeWcqT61vz61PqY86+t1llZfKDZ6AVg4MUijYBFjt3p1sHjkK5Zd3KrigDQtCWvSpAhjXGcHrRWl4I0kax4hhjkJEULb58+lFAHvHi6zNtG5iuWynzFSOteEeMNQa6umUwAkdGFfVXjPSoZLV5jDg4IIFfM/i+xjsNSlcxHY/agDkXH7omVsugyMn9K2fBkkP22cTRhkuItm3P3feueuyrSDBK5PWrVqRaOHhl28cmgBt4/wBnkmgjfLrKcAelX/Dc1xYaks0cDXU7f8sQM4FJoulT69dXDWmF8sb2c962PAOryaD4wWR0jkI/ds78gUAY+tpLDqJlmBV3k8xoyv3PatDUNUludJEVxKXhJ+RMVb8f6jDeeILgwBWSTlmHTNYtvexmBVmjBSI8UAZY2jKqcsOQPSty2eTS7Tz24llX5eK19B03R9YnmYkQIkZkZz/KsfxTdG6MYtY99nD8gb1oA9J/Z2u2s/Ek5lcBZoyzZPU1gfEvxNdw+Mr6GCUhHchhnIIqr8Mb2Kz8RQNck+W6YXB6GsfxyC3iW9ONzGTIb0FAGPLMGmdiSig1aS5jkiMs0u5UG1BVCYkoScZ6ACptPiiNuxY/MOoPrQBJPczJYKFlwGb8hS6fJbzvPb3ZGCCVf1NNitkl3qs2/jJQjpVW3hi80FiREp5oAlijeOLZLH+7J4PtXqfwX0Bda8QGZ08qxtORn+I1xFrbi8lJ3KIsjYtfQfwY0iKO2lcDci/e4wCaAPSbSNRYyi42rCxJAPZa8Y+OMtuttZW2oWw8lwfJkXq9d/4p8Rk3UenaYPMy4SUqOnPSuN+I9quv+J9M0px81qBtUjGM9aAMX4L/AA5tr2wn1a5i8kM+IkK9RXrlzbzWtrNY27/6JHHzu9MdK888WeKb/wAFPYaXBuCT4CYTA/OvUNFjk1Lw/bS3oKzTx5f15oA+T/iFa7PEJvrdCVV8sOx5rmvEdrHfk6lbrsHRoh2PrXs3xB0ZI9VubSSP92DgPjtmvNNQhjhla1VN0eMDH8RoA4eSIEIFbOevtUy4hTDod4+7WsujzSSu3kvGqdFIxWlZaC2s6Rdy274vLfnbjsKAJvhxZTX19cRxjzA8Tb164pND0zUtO8T+Zp1s0zwEvgjAGK7n9n3SVubwzwEbwDHMp9a9jubfw/4bv3iv7JIY7iFibkjI9x7UAfNWra/d6z4pgur7f5iyqCM/d5r6qju3/wCEVtb2GNm8qLJJODjFfPEdvpL+KWuIWWa2ikLIem7mu/1H4q2MFkYpWWONF8sRLzkYoA4jX9csfEXiCc6ioFsmRn0rkvEM2myWfkaOiqq8M4PJqjql0lxqd3PZSbIpyTsrFjgkjfKwSMM8lQTQBreFdPOp61b2052wICzk9xXQeLNX0ua1k07TCEhjOMDuapeHlg0oTXt/MVlddsaEY61y1981xLhSqE7geuaAJtNmFrcMXUSEggitnQ2QkbyNykkD+7XNQNIVxHwT/Ea2NDAjDsT+8bjPrQBreKdQ/tKzSGc5eP8AirR+H2taZc2lz4d8RBTa3I2wSnrG1czrsqqBAU/fjkgd6yykdwyNBH5UidTnpQB1PijwXqmgTyIyC9s/vQSxnPHbpU+keGNZt9OfWbyyMVmq5yxxmqXhjxZqWm3CQtP9pgY7dknO3863/GnijU4rCW0vL7dZTKNluFxigDkYtbNgZLq0kMcpJBQjORWfNcSTQ+ZIvzzsfmA6VoabYLfWpS2KPcYz5bHFUJpBFcxwMMNGfmA5waAKTmQyrb5+Qfx10mlIk5W1iiWSU/8ALf8Aue9YEzpLbCNEJ2OSXIxn2roNJiaLwhcXlvkOzFGPcCgDQ1G9s/CtlJpmnTi81K6/1lyONoJ6UVxSRtJcRgrluGyTzRQB97XlqlxaSkfMzD9a8J+JGkogDSQgybjzivfrA/6MvOfY9q4b4i6IZy1wg3Iy4KAUAfLF/pEQvSj3Sxq3PTpWVdWy2V0I/M82MfxV2XirSGVpEgtG3bjznpXI3NjcwSBJYjtx3NAD7e/FjFJJZyFTJ8rAVf8AD+l2+p6deO05W4ALBe5NZdrZztI1vDCfOYZA6/jWzouiapd5k05cSRHEiE4zQBgSCRJfJYNuXjmrRI/sxkKYctjNX7zy3v1S+AglU4aptD0eTWft9rpal5Y1MinHWgCvoEqTWk9nFu+0bSAqj71Ub8XFsY4JQVk6ba67R9Nk0J7e9kKF+EmUjkH1rmL65lu9WuykLTO82Igqk8UASeH7tre9jZlO9ZBmr2to02o3VyW3RyZ4PUV2uhfDy509rXUfEEZhhZPNEZ7/AFrlPHSQz6lLd6eDFagbdg6ZoA5aK3QfMjkuozzT7eE3NvJJv2EfMR64pDGZrNCJMODz2yKfJLNGiqiBUPy5zQAWlzFNNFHbqUc8M1X73S5XiaK3PQ5IAqzpnh9Q8N2b+PAIZkx0qzqGp/ZtVdrFldSMH0FAFXw3BLayyTuDhOApNe1eBPiXo3hvTFh1JiqyHcxUZINeGzX1zIQQ+0A/NjvUUV+1nqEVxJEGi3A4PIIoA+h0+LHhD+1Y/wCzYCXGWZmXbuP41bt7qx8V6ousw3SWlwCFUE9q8R1nxLomqapaTDSFigRdsmwgZNZ934hjhlay00SJbv3DfdoA+q9ZuPD2qT2mm6j5NzMhXZKMHa31rrokWONUQYRRgD0FfJ3wXmuJvF1vbzyvJbGQMZXOa+rb26isrSa5uHCQwoXdj0AAoA85+L0doYAjFUmkQZYdfvV5F4J0iDxN8QrTT9uILI+Y5z98CjX/ABe3ibUtQ1B5WNszMkCeijgfrXpPwG8IPpkMuu3RJmuo9iKRyBnOaAN7xJ4LstU1C4eGKO3WGHOFX7xxXk11p7+E7n7YY/8ARrqNo2GPWvpGC3MVzO5+bzSD9B6Vi+L/AApZ6/pU1tsSOYjKPjgGgD5vtbm58DW66zYFvIaYMVHpXafEH4l2+peDcIFmF5HwVHKH0rM1XTbnTLO90DWk3LgiKQjj2rlfhpBpV0+o+HdcISQKzWzt0LDpigDhYLm9jswsZKKmQeetQXAYRxZl3s3zMOtaWtRSabdtaX0LeYCQO2RWfZ7oZ/MitCy9CSeAKALGn2txfSFoIflPAJOK7Kw1NvCNqy3dvHd+YPY7a4mady5MExiweFHFSD7S7AXLmRCOcmgC5q2pNqJ/1QMRORjjFZcqtDHuzlu69cUrwRGaNDKYYVP3QM5rWt7V2unZIcoOSW4zQBkQRtdSRDBWBeTxitB723z5VuMAdDU+qXEksJdUWGNONq96yGlEqIiLtDdGoAWaaa6dXQ7p1zu+lVZT8oEbE5PzDoa0bJfLmeVD80fPT71aFrNpuqXULXcQs54z1zw1AGbDaxEQSQOfMJ/i45rbuLiOaGSLWot06L+7YHNW4RorXXnazcq1pH0jTgn8qWbUNES2vHsrdwJBtjLjOPzoA5ux0q8uIzexx7BGTiUPjio4byOymka7tfOZ++au6NZreXUVnNqf2a0lb5j6VreOvC8Ph4wfZ9Uj1Czlxt2jmgDnrjzL2MbUSONTuwK1vDNxPL4c1axaQeWqbkGO9SDwF4hfTzqcunPp+mhQwd2++PpU/hTTria4a6cNBpMYxM+OooAo6e/h6a3jF3uivowACOhNFTeINP0+LVF/sCVbmzY5LY5U0UAfbJRQwbpj0pJ4lmiZHAII71JRQB5V408D3Fw3mWqoRksSBXkPivQbiC58i4ULuG1W7Zr6yIBGCMj0rkvF3hCDWLZxCieZgkBvWgD5auZ5vDk9tKwErBtuUPOKtajqB1ESXejSeVMq7njDbSa6XxH8PdTt5ceXIzBsAY6VgxeHbvTJ0mNvtuIm3kEYDD0oA5h7KfUUFxj/AEpuGVvvZrpfDF3P4T1G2NxG3my4GEPJFdNt8N+IdUthJNJpmogAPHGPlY1S+Ieho2oQvYXyK9ogKuTjcRQA3SdPPim71q7VJI1tt0jiReMCsG18XWGnakLrTrbMlumMEbctVzSPiHPa+Hr/AEu8tRbyTZBuIhy31rno9Oh1ezmuYXhRbWMyMu75nx7UAexJ4lv9Q+E+pax4gbEkrFLcGTeQD+HFeZeEbKbXvDF95eHljYtzycV1XieKWL4EWVzFGFhuLhQVbggVxfgLVV8P6gvmPiyc7JcdcHrQBz+6NPMhY4kXKke9VEiklwhbG055rufiVoNvZXA1bQ4WudJm5aZRnafeuMQv5R5iZm5G1skUAEKeVebZZGCOM+1W3thbbjMDslGUbHFVtjKyNKc8YBPan3V1LiJJX8yNBhVPQUAKhEkIjUg7VPTqarTRTpboPLYMeisMGrmlzW+n6jDcyxiQghvLPQ16drXinw/rul/a20yO1voF2IiL1oA8ws7ER2DXEs0S/wB5CeaauwAtIuHk+4Mc1qfZ7Cci5kgZzyTGozzTNJ02XUtXjhtoLjz5WAjDrgJQB638DvC89xeW17c7Ejh+fa3Vvwrsf2g/FUGleFTosbSNqWpjZGkfVVzyT7VZ0e8j+HvhSW98UCGJ4V2wlT80px90fjXi8k2t+LPFJ1fUrZhf6g3l2NvjhIweP0oAn8B+FrvVNRsLC3jHlxSAysR8vqa+qrWFLa3jhjUKiKFAAwK5/wACeGIvDeiQ27lZLw/PNLjksa6WgAooGcc9aKAMXxNoFvrli8MiRiUj5ZGXJFfL/wATfC2qeHtbgm8lgIzlZIxww+tfXVUNZ0m01ixktb2JZEYYBIyVPqKAPCdRttJ8ZfD+O6CIms26bWDplifrXijfa7cvbyY2xNgkN1r6J1nw7feEDLPY2a3ljIpWY45Ge4FeQah4Jub+5efRLhXfJdoJTgn2AoA5WGKykui7uAfpSpbLIZnilXavTJq/qbfZY1hvNJNrcR8FnXaDWNJFPJG81vEjQ5GQhyaANnw9JY2Mi3Gp7XYdFxmq/ivUm1K4Z7NvKjGMLuwcfSqmy1RWLiVpCMqpHStHR7G81mQfZNCup5h1ZIyVH40AZVwyfZYiXy7Dle9QG2k8l/J4RhnnjFbc/hTVbG9D6lZS2r5+XzF2jFWrXQL3WvEkWm2qZEnQxcg0AHw/axub9rLU2VIiMb2GRWnf6H4fGr/ZLa9t28xsbgvA5+tbN98JtS02UNK6RuV+7u61j6R8MdWl1cNEkG1DuO5+aAM/xx4e0fQ71Y7SdJZVUM21MA/rTIdTivriCKeDy4VXHK9ePSuh8Y6Jq1/G/wDaFnY2RUbI3D4ZsVhaBpqpqH795b25AAjiiG4A0AYE+nm21BxNDKYnYlCqZrT0nRNV1nUof7M02/nKsAjGI7Ac+vavb/h/pfizTLFF1PwvZXiSuSrykB0XtnNdrLP4wJMGm6RY2EH94MMj6DpQByOp6Z4nl8JBPFzRwwxYwizeYWwOMjArhrbxLpghk0w28gDjYAE4/KvRZPAHirUHLatrv2gO24o54T6AV1WlfDvRrPy5J4vPnXqxHWgDwnRvhfrF5qqTWsai0Y7sYxx9KK+p4oo4UCxIqKBgADFFAD6RjtGcE/SlooAKKa67lIBKn1FIu8NggFcfe70AK8aP99Fb6iqF7omnXibLi0icfStGigDmLjwJ4cmdpDpkKzFdokX7w9xXJa18H7G9icxXcnm9VD8gn0r1SigD5d8TfDHVLBgfKkNvjkIuVrZ+Glh4L0JZLrXVVLwHy8SrlSK+iGUMpVgCp6g965zXfBOga3E0d9p8XzfxJ8pFAGD4rsdI8X6JBYab5UlvjMaxrhAe1fO/jfwDrXhG7LXMUc8E5JAjOcLXud/8Kr63jMfhvxFc2EI5WNhnH415l4m0fx14Z1Mya40urafjidQXwKAMPwR4mu9Dtp9HngivdKuvmaKbqn0qtqZ8NXUrW2kWjwXQPJ28fhWzHpmg+I8TxXj2Fwq/Nng59K3dD+EM2oywXdvqTPDnO8UAeP3UQVpkuS+1Gx05pbOI3ULKqKI1/iPWvoDxT8F4o9JkvNKnmu9VUgiJ8bH9q8c1/wAN6xZmVtY0640twwA2Idh/GgDAmha0ZJJI96jgZFNimaaVjI5jXqcdq6DTfD+oap+4imSSNELFnbHArGl+xWjsFk86XJXYO5oAs6Zqi6beQ3UGZnRsmNv469PtfirDa6jBeXvh+1hBX5I4h8zN9K47wjomsa9KkWk+Hy9wnBnuFKooPfNe0eEPhhY+HJI7zV0bWdckG6NWGYo2/wDrUAYCWt74tuh4n+IETxaXGf8AiW6Qo5lbsSv1r0TwB4Tms7qfW9aVTqNxjyocfLap2VfetzSNFkNyuo6yUn1ED5Av3IB6L/jW/QAUUUUAIpyM0tFFABRRRQAjqrqVcBlIwQec15544+HcGpr9s0VjY30fzAxD7xr0Skwc5zxjpQB853viC60B/wCz/iD4eXUrd/lWfZlh71iXfhHw3rKG68Ia01tMfvW0uF2n0r6d1DTrTUIil5bxTDGBuXJFeX+KvgnpGpM1zo9xLp16eSyn5WNAHhtx4D8WQXaiKOO7P8JBzmvRPCVz8SvC1m/2fw/Dc2/Vozx+tQmw8eeE50UW5niiOBInzbh7V6T4Y8Ya9dtGl3o8ro38ZG00Aeea34917WXNl4i8JGOFe+wn8jVbwv4m/wCEfunl0zw/LJc4IRWjPGa+i0AniRp4AGP8LAHFOW2gVtywRBvUKM0AfOzeEviL47vn1bUbr+y1Y4ihJ2gL9K6/SPhFfQSxT3niS5MqjlYhwa9fooA88u/hXpeoSxyaneXlyydAWAFdH4b8H6H4cBOl2MccrdZWGWP410FBOKACioZpWTb5cTSFvfGKrxXNxNcbFhMaDqx55oAvUVWt4HVi08hkfPHYD8Ks0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNdFkQo6hlPBDDINFFAHD+J/hh4f1wySrAbO4fJLwcAn3Fcovw98YaDbmDw3rqSQbtyxykrt9qKKANJZPipBCIfs2lSkDHneYM/lWLrOi/E3xHYPYavDpjWxOdysFNFFAGFpXwK1xpHN7rS2iNxiIluPSvQvCfwe8MaFHG01qt9coc+bMM8/SiigD0EW6xxLHbhYUHZFA4qWNFjUKgwKKKAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9650=[""].join("\n");
var outline_f9_27_9650=null;
var title_f9_27_9651="Echo vs CMR LVH in HCM";
var content_f9_27_9651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Echo vs CMR LVH in HCM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two-dimensional stop-frame echocardiogram (A) and comparative cardiac magnetic resonance (CMR, panel B) images acquired in short axis plane in end diastole at mitral valve level. In panel A, the echocardiogram shows normal thickness in all LV wall segments, including ventricular septum and contiguous portion of anterolateral free wall (*). In panel B, CMR image showing segmental area of hypertrophy confined to anterolateral LV free wall (20 mm) and small portion of contiguous anterior septum (*), which was identified only with CMR, in the same cross-sectional plane as echocardiogram shown in panel A.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; AVS: anterior ventricular septum; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112:855. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9651=[""].join("\n");
var outline_f9_27_9651=null;
var title_f9_27_9652="Sacrosidase: Patient drug information";
var content_f9_27_9652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sacrosidase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41619?source=see_link\">",
"     see \"Sacrosidase: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/12/16579?source=see_link\">",
"     see \"Sacrosidase: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sucraid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sucraid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an enzyme loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702897",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sacrosidase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a glycerin, papain, or yeast allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695448",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water or milk.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give approximately",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       of the dose before, and the rest of the dose during, each meal or snack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12112 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9652=[""].join("\n");
var outline_f9_27_9652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219729\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219730\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015854\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015853\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015858\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015859\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015861\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015856\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015857\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015862\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015863\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41619?source=related_link\">",
"      Sacrosidase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/12/16579?source=related_link\">",
"      Sacrosidase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_27_9653="Auranofin: Patient drug information";
var content_f9_27_9653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Auranofin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"     see \"Auranofin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/28/18884?source=see_link\">",
"     see \"Auranofin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ridaura&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ridaura&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700331",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is very strong. It may stop your bone marrow from making some of the cells that your body needs. You will need weekly blood work to watch for side effects. Tell your doctor right away about any fever, sore throat, signs of infection, bleeding, shortness of breath, or feeling tired. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 3 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to auranofin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3540800",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a very bad reaction to gold products in the past.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a blood disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel disease such as Crohn's disease or ulcerative colitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12009 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9653=[""].join("\n");
var outline_f9_27_9653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031295\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031297\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031296\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031301\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031302\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031304\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031299\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031300\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031305\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031306\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=related_link\">",
"      Auranofin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/28/18884?source=related_link\">",
"      Auranofin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_27_9654="Peanut, tree nut, and seed allergy: Diagnosis";
var content_f9_27_9654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peanut, tree nut, and seed allergy: Diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9654/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9654/contributors\">",
"     Hugh A Sampson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9654/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9654/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9654/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9654/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/27/9654/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut, tree nut, and seed allergies are some of the most common food allergies in both children and adults. These allergies tend to cause severe reactions and usually persist over time.",
"   </p>",
"   <p>",
"    The diagnosis of peanut, tree nut, and seed allergies is presented in this topic review. A general discussion of the diagnosis of food allergy is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features and management of these allergies are discussed separately as is treatment for food-induced anaphylaxis. General discussions of food allergy are presented separately in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38457?source=see_link\">",
"     \"Peanut, tree nut, and seed allergy: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32919?source=see_link\">",
"     \"Peanut, tree nut, and seed allergy: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IgE-MEDIATED REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unequivocal history of an immediate reaction consisting of typical allergic symptoms following the isolated ingestion of a peanut, tree nut, or seed product, supported by positive tests for specific IgE antibodies, is usually sufficient to establish the diagnosis for suspected IgE-mediated reactions. Either skin prick tests or in vitro tests for IgE are usually performed initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the exception of in vitro immunoassays for specific IgE (which are still erroneously referred to as IgE RAST tests), other diagnostic allergy procedures, including skin testing and food challenges, should be performed by allergy specialists with training in the management of serious allergic reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Double-blind, placebo-controlled oral food challenges (DBPCFC) are the gold standard for the diagnosis of food allergy. A clinician-supervised oral food challenge is required if the history and IgE test results do not clearly indicate an allergy. The use of challenges in the diagnosis of food allergy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The skin prick test wheal size and level of specific IgE correlate with the likelihood of an allergic reaction, but by themselves are not diagnostic of food allergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fairly consistent positive predictive values for various allergy tests have been determined for peanut, although similar data for tree nuts and seeds are limited, and testing does not appear to be as predictive for some of these foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies using the ImmunoCAP (ThermoFisher Scientific, Uppsala, Sweden) have demonstrated that an IgE level of 13 to 15",
"      <span class=\"nowrap\">",
"       kU",
"       <sub>",
"        A",
"       </sub>",
"       /L",
"      </span>",
"      to peanut has a 95 to 99 percent positive predictive value (PPV) for clinical reactivity to peanut in patients with suggestive histories of allergic reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/1,3-6\">",
"       1,3-6",
"      </a>",
"      ]. However, as noted previously, over 25 percent of children with peanut-specific IgE &gt;15",
"      <span class=\"nowrap\">",
"       kU",
"       <sub>",
"        A",
"       </sub>",
"       /L",
"      </span>",
"      had negative food challenges in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/7\">",
"       7",
"      </a>",
"      ]. False positives occur more frequently in areas where birch pollen sensitivity is common, due to cross-reactivity between the birch pollen protein, Bet v 1, and the peanut protein, Ara h 8 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/8\">",
"       8",
"      </a>",
"      ]. The use of component-resolved diagnostic assays (ie, quantitation of IgE to specific food proteins) suggests that elevated levels of Ara h 2-specific IgE (&gt;0.35",
"      <span class=\"nowrap\">",
"       kU",
"       <sub>",
"        A",
"       </sub>",
"       /L)",
"      </span>",
"      are more diagnostic of systemic reactivity to peanut than whole peanut-specific IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/9\">",
"       9",
"      </a>",
"      ], and isolated sensitization to Ara h 8 indicates clinical tolerance or only mild reactivity in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/10\">",
"       10",
"      </a>",
"      ]. Thus, elevated peanut-specific IgE antibody levels alone are not diagnostic of food allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link&amp;anchor=H6106817#H6106817\">",
"       \"Diagnostic evaluation of food allergy\", section on 'Component testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      On skin prick testing, a wheal size of &ge;8 mm has a 95 to 100 percent PPV for peanut allergy in children with suspected peanut allergy in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/3,6,11-14\">",
"       3,6,11-14",
"      </a>",
"      ]. A wheal of &ge;4 mm has a PPV of approximately 100 percent in children &le; 2 years of age. However, in one study nearly one-half of the children with peanut skin test wheal sizes &gt;8 mm had a negative food challenge; therefore, skin testing alone is not diagnostic of food allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sensitivities and negative predictive values at these decision points or cutoff levels are generally poor. Patients with negative tests, particularly specific IgE, may still be clinically allergic. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnostic pitfalls'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, these test results do not reflect the severity of the allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/4,15,16\">",
"     4,15,16",
"    </a>",
"    ]. Diagnostic tools are under investigation that may help predict reaction severity, and also distinguish between patients who are only sensitized versus those who are clinically allergic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link\">",
"     \"Future diagnostic tools for food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history is important for guiding the diagnostic evaluation in a patient with suspected peanut, tree nut, or seed allergy. Foods suspected of provoking an IgE-mediated reaction may be evaluated with skin prick tests (SPT), which indicate whether or not the patient has IgE antibodies to the suspected food. The larger the mean wheal diameter of the SPT, the greater the likelihood that the food being tested is the cause of the allergic reaction.",
"   </p>",
"   <p>",
"    Obtaining food-specific IgE levels (eg, ImmunoCAP) to foods suspected by history or by the presence of positive skin tests provide further evidence regarding whether or not a specific food is the cause of a suspected allergic reaction, as described previously. However, an oral food challenge should be performed if these tests are positive in the absence of a suggestive history or in the presence of an equivocal history. Similarly, an oral food challenge should be performed to establish the diagnosis if these tests are negative in the face of a convincing history.",
"   </p>",
"   <p>",
"    We generally do not test related foods if they are already in the diet and were eaten recently. We skin test to sesame in patients with peanut allergy if they have never ingested sesame or the history of exposure is unclear. If the test is positive, we check sesame-specific IgE by ImmunoCAP. We suggest a challenge to sesame if the level is &le;20",
"    <span class=\"nowrap\">",
"     kU",
"     <sub>",
"      A",
"     </sub>",
"     /L.",
"    </span>",
"    We advise avoidance if the level is &gt;20",
"    <span class=\"nowrap\">",
"     kU",
"     <sub>",
"      A",
"     </sub>",
"     /L,",
"    </span>",
"    although we will perform a clinician-supervised food challenge to sesame in these patients also if the",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    would like to have sesame in the diet. If the skin test is negative, sesame may be introduced into the diet. Patients with peanut allergy who are not ingesting tree nuts should also be tested to tree nuts prior to introducing them into their diet. We follow a similar approach to that outlined above for sesame. We generally suggest avoidance and will not perform a challenge if the tree nut-specific IgE level is &gt;15",
"    <span class=\"nowrap\">",
"     kU",
"     <sub>",
"      A",
"     </sub>",
"     /L",
"    </span>",
"    (except for hazelnut, which tends to run higher levels in patients with concomitant birch allergy due to cross-reactivity to birch pollen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32919?source=see_link&amp;anchor=H4#H4\">",
"     \"Peanut, tree nut, and seed allergy: Management\", section on 'Clinical scenarios'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OTHER REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE tests are expected to be negative if the symptoms do not suggest an IgE-mediated reaction, such as some patients with possible peanut allergy who present with atopic dermatitis or allergic gastrointestinal disorders. Atopy patch testing may provide additional information in these cases, but to date such tests have not been standardized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H12#H12\">",
"     \"Future diagnostic tools for food allergy\", section on 'Atopy patch testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=see_link&amp;anchor=H16#H16\">",
"     \"Contact dermatitis in children\", section on 'Patch testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC PITFALLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several factors that can make the diagnosis of peanut, tree nut, and seed allergy challenging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitization does not equal clinical allergy. In a survey of the general population in the United States, 9 percent of participants were sensitized (positive skin test) to peanut, whereas the prevalence of clinical allergy in this population is around 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/17\">",
"       17",
"      </a>",
"      ]. Similarly, in a United Kingdom population-based birth cohort, 12 percent were sensitized to peanut at eight years of age, but only 2 percent were allergic [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The higher rate of sensitization than clinical allergy may be due in part to cross-reactions to homologous plant allergens, such as birch and grass pollen [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Thus, the positive predictive value of skin testing to peanut is poor if the test is performed in individuals who have a low probability of peanut allergy based upon clinical history.",
"      <br/>",
"      <br/>",
"      In an individual who is &ldquo;sensitized&rdquo; (ie, has never ingested peanuts or tree nuts because of previous positive skin or in vitro tests), the tests should be repeated and, unless both are strongly suggestive of clinical reactivity (skin prick test reaction &ge;8 mm and specific IgE &ge;2",
"      <span class=\"nowrap\">",
"       kU",
"       <sub>",
"        A",
"       </sub>",
"       /L),",
"      </span>",
"      a clinician-supervised oral food challenge should be performed to establish clinical reactivity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32919?source=see_link&amp;anchor=H4#H4\">",
"       \"Peanut, tree nut, and seed allergy: Management\", section on 'Clinical scenarios'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of undetectable IgE levels (&lt;0.35",
"      <span class=\"nowrap\">",
"       kU",
"       <sub>",
"        A",
"       </sub>",
"       /L)",
"      </span>",
"      does not exclude clinical reactivity to that food [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/1,3,4,20\">",
"       1,3,4,20",
"      </a>",
"      ]. The rate of positive food challenges or convincing clinical history of reactivity to peanut in those with peanut-specific IgE levels &lt;0.35",
"      <span class=\"nowrap\">",
"       kU",
"       <sub>",
"        A",
"       </sub>",
"       /L",
"      </span>",
"      ranges from approximately 4 to 28 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9654/abstract/1,3-5,14,16\">",
"       1,3-5,14,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergies to foods other than peanut, tree nuts, and seeds should be considered in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other diagnoses to consider include exercise-induced anaphylaxis, idiopathic urticaria and anaphylaxis, and psychologic factors, such as anxiety and panic disorders and hyperventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=see_link\">",
"     \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=see_link\">",
"       \"Patient information: Peanut allergy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical history is important for guiding the diagnostic evaluation in a patient with suspected peanut, tree nut, or seed allergy. An immediate reaction consisting of typical allergic symptoms following the isolated ingestion of a peanut, tree nut, or seed product strongly suggests an IgE-mediated allergy to that food. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'IgE-mediated reactions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"       \"History and physical examination in the patient with possible food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A positive test for specific IgE antibodies (skin prick test or in vitro test) is usually sufficient to establish the diagnosis for a suspected IgE-mediated reaction in the setting of an unequivocal history. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'IgE-mediated reactions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"       \"Diagnostic evaluation of food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A clinician-supervised oral food challenge is required if the history and IgE test results do not clearly indicate an allergy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'IgE-mediated reactions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"       \"Oral food challenges for diagnosis and management of food allergies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IgE tests are expected to be negative if the symptoms do not suggest an IgE-mediated reaction. Atopy patch testing may provide additional information in these cases, but this test remains to be standardized. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Other reactions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H12#H12\">",
"       \"Future diagnostic tools for food allergy\", section on 'Atopy patch testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are several factors that can make the diagnosis of peanut, tree nut, and seed allergy challenging. First, sensitization does not equal clinical allergy. Second, the presence of undetectable IgE levels (&lt;0.35",
"      <span class=\"nowrap\">",
"       kU",
"       <sub>",
"        A",
"       </sub>",
"       /L)",
"      </span>",
"      does not exclude clinical reactivity to that food. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic pitfalls'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/1\">",
"      Maloney JM, Rudengren M, Ahlstedt S, et al. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J Allergy Clin Immunol 2008; 122:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/2\">",
"      Zavalkoff S, Kagan R, Joseph L, et al. The value of sesame-specific IgE levels in predicting sesame allergy. J Allergy Clin Immunol 2008; 121:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/3\">",
"      Sicherer SH, Sampson HA. Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol 2007; 120:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/4\">",
"      Sampson HA, Ho DG. Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 1997; 100:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/5\">",
"      Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001; 107:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/6\">",
"      Pucar F, Kagan R, Lim H, Clarke AE. Peanut challenge: a retrospective study of 140 patients. Clin Exp Allergy 2001; 31:40.",
"     </a>",
"    </li>",
"    <li>",
"     Beyer K, personal communication, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/8\">",
"      Vereda A, van Hage M, Ahlstedt S, et al. Peanut allergy: Clinical and immunologic differences among patients from 3 different geographic regions. J Allergy Clin Immunol 2011; 127:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/9\">",
"      Nicolaou N, Poorafshar M, Murray C, et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010; 125:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/10\">",
"      Asarnoj A, Nilsson C, Lidholm J, et al. Peanut component Ara h 8 sensitization and tolerance to peanut. J Allergy Clin Immunol 2012; 130:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/11\">",
"      Sporik R, Hill DJ, Hosking CS. Specificity of allergen skin testing in predicting positive open food challenges to milk, egg and peanut in children. Clin Exp Allergy 2000; 30:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/12\">",
"      Ho MH, Heine RG, Wong W, Hill DJ. Diagnostic accuracy of skin prick testing in children with tree nut allergy. J Allergy Clin Immunol 2006; 117:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/13\">",
"      Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. Pediatr Allergy Immunol 2004; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/14\">",
"      Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE testing. J Allergy Clin Immunol 2005; 115:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/15\">",
"      Astier C, Morisset M, Roitel O, et al. Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. J Allergy Clin Immunol 2006; 118:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/16\">",
"      Ranc&eacute; F, Abbal M, Lauwers-Canc&egrave;s V. Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays. J Allergy Clin Immunol 2002; 109:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/17\">",
"      Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005; 116:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/18\">",
"      Asarnoj A, Ostblom E, Ahlstedt S, et al. Reported symptoms to peanut between 4 and 8 years among children sensitized to peanut and birch pollen - results from the BAMSE birth cohort. Allergy 2010; 65:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/19\">",
"      Niggemann B, Schmitz R, Schlaud M. The high prevalence of peanut sensitization in childhood is due to cross-reactivity to pollen. Allergy 2011; 66:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9654/abstract/20\">",
"      Gangur V, Kelly C, Navuluri L. Sesame allergy: a growing food allergy of global proportions? Ann Allergy Asthma Immunol 2005; 95:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2394 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-42E0F5FCD1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9654=[""].join("\n");
var outline_f9_27_9654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IgE-MEDIATED REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OTHER REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC PITFALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=related_link\">",
"      Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=related_link\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=related_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38457?source=related_link\">",
"      Peanut, tree nut, and seed allergy: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32919?source=related_link\">",
"      Peanut, tree nut, and seed allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_27_9655="Bell's palsy: Prognosis and treatment in adults";
var content_f9_27_9655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bell's palsy: Prognosis and treatment in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9655/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9655/contributors\">",
"     Michael Ronthal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9655/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9655/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9655/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9655/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/27/9655/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bell's palsy is the appellation commonly used to describe an acute peripheral facial palsy of unknown cause. However, the terms \"Bell's palsy\" and \"idiopathic facial paralysis\" may no longer be considered synonymous. A peripheral facial palsy is a clinical syndrome of many causes, and evaluation requires more than a superficial examination.",
"   </p>",
"   <p>",
"    This review will discuss the treatment and prognosis of Bell's palsy. Other clinical aspects of this disorder are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of Bell's palsy is related to the severity of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/1\">",
"     1",
"    </a>",
"    ]. A simple rule is that clinically incomplete lesions tend to recover. The House-Brackmann grading system (",
"    <a class=\"graphic graphic_table graphicRef70562 \" href=\"UTD.htm?40/31/41468\">",
"     table 1",
"    </a>",
"    ) was devised both as a clinical indicator of severity and also an objective record of progress [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/2\">",
"     2",
"    </a>",
"    ]. On this scale, grades I and II have good outcomes, grades III and IV characterize moderate dysfunction, and grades V and VI portend a poor result. Other grading systems (eg, the",
"    <a class=\"external\" href=\"file://sunnybrook.ca/uploads/FacialGradingSystem.pdf\">",
"     Sunnybrook facial grading system",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/3\">",
"     3",
"    </a>",
"    ]) are similar and sometimes favored [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Statistically, the natural history without treatment was described in a study of 1011 patients in 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/8\">",
"     8",
"    </a>",
"    ]. One-third had an incomplete paralysis, and two-thirds had complete paralysis. Overall, 85 percent showed signs of recovery within three weeks, 71 percent had complete recovery, 13 percent had slight sequelae, and 16 percent had residual weakness, synkinesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contracture. Patients with incomplete lesions had a 94 percent rate of return to normal function, while only 60 percent of those with clinically complete lesions returned to normal function. Herpes zoster is associated with more severe paresis and a worse prognosis compared with \"idiopathic\" Bell's palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is favorable if some recovery is seen within the first 21 days of onset [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/10\">",
"     10",
"    </a>",
"    ]. A diagnosis of Bell's palsy is doubtful if some facial function - however small - has not returned within three to four months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link&amp;anchor=H7#H7\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In severe lesions that recover, the outgrowth of new axons from the injury site is not discretely directed but is disorganized and misdirected; on volitional activation of the facial nerve, a mass action of facial musculature or synkinesis ensues. Thus, on blinking there is twitching of the angle of the mouth, and on smiling the eye may close or wink. Similarly, with misdirected autonomic fibers, a salivary stimulus may result in excess lacrimation, the syndrome of \"crocodile tears.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent attacks of idiopathic facial palsy on either the ipsilateral or contralateral side have been observed 7 to 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In the largest series, which followed 1980 patients with Bell's palsy, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The recurrence rate was 7 percent, and the mean time to recurrence was approximately 10 years.",
"     </li>",
"     <li>",
"      A third or fourth attack was unusual, occurring in 3 and 1.5 percent of cases respectively.",
"     </li>",
"     <li>",
"      Recurrence did not portend a worse prognosis for recovery. None of the patients with recurrent Bell's palsy who were imaged by head CT had a facial nerve neuroma. In addition, 77 patients were followed for a mean of 33 years (range 2.8 to 60 years) after the initial episode, and none developed signs of a tumor or showed progressive facial nerve dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy may be a risk factor for recurrence of Bell's palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/15\">",
"     15",
"    </a>",
"    ]. Some patients with recurrent attacks have a family history of multiple attacks, suggesting a genetic predisposition to Bell's palsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link&amp;anchor=H3#H3\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\", section on 'Epidemiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of recurrent facial nerve palsy includes the Melkersson-Rosenthal syndrome, characterized by facial paralysis, episodic facial swelling, and a fissured tongue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link&amp;anchor=H14#H14\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\", section on 'Melkersson-Rosenthal syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EYE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe cases of Bell's palsy, the cornea may be at risk because of poor eye lid closure and reduced tearing, which may result in drying and abrasion. If there is concomitant fifth nerve loss, the risk for blindness due to corneal trauma is significant.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    should be applied every hour while the patient is awake, and ophthalmic ointments should be used at night [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/16\">",
"     16",
"    </a>",
"    ]. Protective glasses or goggles should be prescribed. Patches can be used at night, but tape should not be placed directly on the eyelid since the patch could slip and abrade the cornea. Rarely tarsorrhaphy or temporary implantation of a gold weight into the upper lid is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID AND ANTIVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of pharmacologic therapy for Bell's palsy is early short-term oral glucocorticoid treatment, which is established as effective by randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/17-23\">",
"     17-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The suspicion that Bell's palsy is caused by herpes simplex virus in most patients led to trials of antiviral therapy. Compared with placebo, these trials found no benefit for antiviral therapy alone. However, the data are conflicting with regard to the possibility of additional benefit when antiviral agents are administered with glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of meta-analyses have evaluated trials testing glucocorticoids and antiviral therapy for Bell&rsquo;s palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. The following examples illustrate the range of the findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis involving 18 trials and 2786 patients, treatment with glucocorticoids alone was associated with a reduced risk of unfavorable recovery (relative risk [RR] 0.69, 95% CI 0.55-0.87), whereas treatment with antiviral agents alone was not (RR 1.14, 95% CI 0.80-1.62) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/24\">",
"       24",
"      </a>",
"      ]. In pooled data from eight trials, the same meta-analysis found a trend towards a reduced risk of unfavorable recovery for combined antiviral and glucocorticoid treatment compared with glucocorticoid treatment alone, but the outcome just missed statistical significance (RR 0.75, 95% CI 0.56-1.0).",
"     </li>",
"     <li>",
"      In a second meta-analysis of six trials and 1145 patients, there was no significant benefit of combined antiviral and glucocorticoid treatment for achieving at least partial facial muscle recover (odds ratio 1.5, 95% CI 0.83-2.69) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methodologic differences probably account for the divergent results of these two meta-analyses. Neither excludes the possibility of marginal benefit when antiviral therapy is combined with glucocorticoids. However, the trend towards benefit was driven largely by the smaller, lower quality trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the two highest quality randomized controlled trials, glucocorticoid treatment alone was effective for Bell's palsy, while antiviral treatment showed no benefit when given alone or when combined with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/21,23\">",
"     21,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial studied 829 adults with Bell's palsy who were randomly assigned within 72 hours of onset to one of four treatment groups [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/23\">",
"       23",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Placebo plus placebo",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      (60 mg daily for five days, then tapered by 10 mg daily, for a total treatment length of 10 days) plus placebo",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      (1000 mg three times daily for seven days) plus placebo",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      (10 days) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (seven days)",
"     </li>",
"     <li>",
"      At one-year follow-up, the time to recovery was significantly shorter for patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      compared with those not treated with prednisolone (hazard ratio [HR] 1.4, 95% CI 1.18-1.64) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/23\">",
"       23",
"      </a>",
"      ]. In contrast, time to recovery was no different for patients treated or not treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (HR 1.01, 95% CI 0.85-1.19). Furthermore, time to recovery with the addition of valacyclovir to prednisolone was no better than with prednisolone alone. In a separate analysis, treatment with prednisolone significantly reduced the proportion of patients at one year with mild and moderate sequelae (ie, facial asymmetry, facial weakness, and synkinesis) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An earlier trial evaluated 551 adults (age 16 or older) who were recruited within 72 hours after symptom onset and assigned to either 10 days of treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (25 mg twice daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg five times daily), both prednisolone and acyclovir, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/21\">",
"       21",
"      </a>",
"      ]. Outcome data were available for 496 patients. The following observations were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The primary outcome measure, complete recovery of facial function, was significantly more likely for patients assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      than for those not assigned to prednisolone at both three months (83 versus 64 percent, adjusted odds ratio [OR] 2.44, 95% CI 1.55-3.84) and nine months (94 versus 82 percent, adjusted OR 3.32, 95% CI 1.72-6.44) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/21\">",
"       21",
"      </a>",
"      ]. The corresponding number needed to treat to achieve one additional complete recovery was six and eight at the two time periods.",
"     </li>",
"     <li>",
"      There was no significant difference in the rate of complete facial recovery for patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg five times daily) compared with those not assigned to acyclovir at either three months (71 versus 76 percent, adjusted OR 0.86, 95% CI 0.55-1.32) or nine months (85 versus 91 percent, adjusted OR 0.61, 95% CI 0.33-1.11) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/21\">",
"       21",
"      </a>",
"      ]. Similarly, there was no additional benefit of combined acyclovir and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      treatment compared to prednisolone alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of other lower quality trials have suggested benefit or a trend towards benefit for antiviral therapy combined with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/17,20,22\">",
"     17,20,22",
"    </a>",
"    ]. The largest such trial randomly assigned 221 patients within seven days of Bell's palsy onset to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg twice daily for five days) plus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or placebo plus oral prednisolone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of complete recovery was significantly higher in the combined",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      group than in the placebo plus prednisolone group (97 versus 90 percent).",
"     </li>",
"     <li>",
"      A subgroup analysis found that the benefit of combined therapy correlated with increasing severity of baseline facial palsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The strength of these results is limited by methodologic issues, including lack of blinding among outcome assessors and a relatively high dropout rate of 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment choices",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend early treatment with oral glucocorticoids for all patients with Bell's palsy, consistent with guidelines from the American Academy of Neurology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/31\">",
"     31",
"    </a>",
"    ]. Treatment should preferably begin within three days of symptom onset. Our suggested regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for one week.",
"   </p>",
"   <p>",
"    The two largest and most rigorous clinical trials have found no additional benefit for antiviral therapy and its use is no longer routinely recommended. However, it is possible, but not proven, that the addition of antivirals to glucocorticoids is beneficial, particularly for the subgroup of patients with severe facial palsy. Until certainty is reached, we suggest early combined therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60 to 80 mg per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (1000 mg three times daily) for one week for patients with severe facial palsy at presentation, defined as House-Brackmann grade IV or higher (",
"    <a class=\"graphic graphic_table graphicRef70562 \" href=\"UTD.htm?40/31/41468\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence regarding surgical facial nerve decompression and electrical nerve stimulation for the treatment of Bell's palsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgical decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of surgical decompression of the facial nerve is mentioned only for discussion, as it is not a currently recommended treatment. A systematic review published in 2011 found only two small randomized trials comparing surgery and non-surgical control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/32\">",
"     32",
"    </a>",
"    ]. The methodologic quality of both trials was very low, and there was no difference in outcome between the treatment groups in either trial. The authors concluded that there is insufficient evidence to decide whether surgery for Bell&rsquo;s palsy is beneficial or harmful. Similar conclusions were reached in an earlier systematic review from the American Academy of Neurology that identified four nonrandomized, prospective studies comparing patients treated with surgery versus no surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Permanent unilateral hearing loss is the most common serious side effect among patients undergoing facial nerve decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Other risks reported with middle cranial fossa craniectomy include seizures, leakage of cerebrospinal fluid, and facial nerve injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An uncontrolled study suggested that decompression may be of benefit in patients with profound facial nerve dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/34\">",
"     34",
"    </a>",
"    ], and surgical middle cranial fossa decompression of the labyrinthine segment of the facial nerve has been advocated in patients with motor nerve conduction studies (NCS) that show at least 90 percent degeneration of the facial nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link&amp;anchor=H9#H9\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\", section on 'Electrodiagnostic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the results of motor NCS cannot dictate when to operate since test results begin to show abnormalities 72 hours after neural degeneration, a time too late for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, surgical decompression should not be undertaken if facial paralysis has been present for 14 or more days, since severe degeneration of the facial nerve is probably irreversible after two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical nerve stimulation has been used to try to promote motor recovery in patients with Bell's palsy. Case reports and small case series have suggested the possibility of some benefit with such treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. However, in the absence of controlled trials of electrical stimulation, and given the lack of data even that such stimulation is safe (ie, not harmful to patients with Bell's palsy), we recommend against its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LONG-TERM SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up is essential for eye care, psychological support, and management of long-term sequelae related to Bell's palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/16\">",
"     16",
"    </a>",
"    ]. A multidisciplinary approach may be helpful for patients with persistent severe deficits. Botulinum toxin injections may benefit patients with synkinesis, facial spasm or hyperlacrimation (&ldquo;crocodile tears&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/16,40,41\">",
"     16,40,41",
"    </a>",
"    ]. Cosmetic and functional improvement may be possible with facial reanimation surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9655/abstract/16,42,43\">",
"     16,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/13/32977?source=see_link\">",
"       \"Patient information: Bell's palsy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=see_link\">",
"       \"Patient information: Bell's palsy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognosis of Bell's palsy is related to the severity of the lesion. A simple rule is that clinically incomplete lesions tend to recover. The prognosis is favorable if some recovery is seen within the first 21 days of onset. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In severe cases of Bell's palsy, the cornea may be at risk because of poor eye lid closure and reduced tearing. Proper eye care measures should be implemented. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with Bell's palsy, we recommend early treatment with oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment should preferably begin within three days of symptom onset. Our suggested regimen is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (60 to 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for one week. For the subgroup of patients with severe facial palsy at presentation, defined as House-Brackmann grade IV or higher (",
"      <a class=\"graphic graphic_table graphicRef70562 \" href=\"UTD.htm?40/31/41468\">",
"       table 1",
"      </a>",
"      ), we suggest early combined therapy with prednisone (60 to 80 mg per day) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (1000 mg three times daily) for one week rather than glucocorticoids alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Glucocorticoid and antiviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow-up is essential for eye care, psychological support, and management of long-term sequelae related to Bell's palsy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term sequelae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sunderland S. Nerve and Nerve Injuries, 2nd ed, Churchill Livingstone, London 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/2\">",
"      House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985; 93:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/3\">",
"      Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. Otolaryngol Head Neck Surg 1996; 114:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/4\">",
"      Chee GH, Nedzelski JM. Facial nerve grading systems. Facial Plast Surg 2000; 16:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/5\">",
"      Berg T, Jonsson L, Engstr&ouml;m M. Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy. Otol Neurotol 2004; 25:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/6\">",
"      Coulson SE, Croxson GR, Adams RD, O'Dwyer NJ. Reliability of the \"Sydney,\" \"Sunnybrook,\" and \"House Brackmann\" facial grading systems to assess voluntary movement and synkinesis after facial nerve paralysis. Otolaryngol Head Neck Surg 2005; 132:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/7\">",
"      Marsk E, Bylund N, Jonsson L, et al. Prediction of nonrecovery in Bell's palsy using Sunnybrook grading. Laryngoscope 2012; 122:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/8\">",
"      Peitersen E. The natural history of Bell's palsy. Am J Otol 1982; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/9\">",
"      Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 2002; :4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/10\">",
"      Jabor MA, Gianoli G. Management of Bell's palsy. J La State Med Soc 1996; 148:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/11\">",
"      CAWTHORNE T, HAYNES DR. Facial palsy. Br Med J 1956; 2:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/12\">",
"      Boddie HG. Recurrent Bell's palsy. J Laryngol Otol 1972; 86:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/13\">",
"      Hallmo P, Elverland HH, Mair IW. Recurrent facial palsy. Arch Otorhinolaryngol 1983; 237:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/14\">",
"      Pitts DB, Adour KK, Hilsinger RL Jr. Recurrent Bell's palsy: analysis of 140 patients. Laryngoscope 1988; 98:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/15\">",
"      McGregor JA, Guberman A, Amer J, Goodlin R. Idiopathic facial nerve paralysis (Bell's palsy) in late pregnancy and the early puerperium. Obstet Gynecol 1987; 69:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/16\">",
"      Holland NJ, Weiner GM. Recent developments in Bell's palsy. BMJ 2004; 329:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/17\">",
"      Adour KK, Ruboyianes JM, Von Doersten PG, et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol 1996; 105:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/18\">",
"      Antunes ML, Fukuda Y, Testa JR. [Clinical treatment of Bell's palsy: comparative study among valaciclovir plus deflazacort, deflazacort and placebo]. Acta AWHO 2000; 19:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/19\">",
"      Kawaguchi K, Inamura H, Abe Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope 2007; 117:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/20\">",
"      Hato N, Yamada H, Kohno H, et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-controlled study. Otol Neurotol 2007; 28:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/21\">",
"      Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007; 357:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/22\">",
"      Yeo SG, Lee YC, Park DC, Cha CI. Acyclovir plus steroid vs steroid alone in the treatment of Bell's palsy. Am J Otolaryngol 2008; 29:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/23\">",
"      Engstr&ouml;m M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008; 7:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/24\">",
"      de Almeida JR, Al Khabori M, Guyatt GH, et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA 2009; 302:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/25\">",
"      Quant EC, Jeste SS, Muni RH, et al. The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ 2009; 339:b3354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/26\">",
"      van der Veen EL, Rovers MM, de Ru JA, van der Heijden GJ. A small effect of adding antiviral agents in treating patients with severe Bell palsy. Otolaryngol Head Neck Surg 2012; 146:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/27\">",
"      Salinas RA, Alvarez G, Daly F, Ferreira J. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2010; :CD001942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/28\">",
"      Lockhart P, Daly F, Pitkethly M, et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2009; :CD001869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/29\">",
"      Berg T, Bylund N, Marsk E, et al. The effect of prednisolone on sequelae in Bell's palsy. Arch Otolaryngol Head Neck Surg 2012; 138:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/30\">",
"      Gilden DH, Tyler KL. Bell's palsy--is glucocorticoid treatment enough? N Engl J Med 2007; 357:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/31\">",
"      Gronseth GS, Paduga R, American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012; 79:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/32\">",
"      McAllister K, Walker D, Donnan PT, Swan I. Surgical interventions for the early management of Bell's palsy. Cochrane Database Syst Rev 2011; :CD007468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/33\">",
"      Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/34\">",
"      Yanagihara N, Hato N, Murakami S, Honda N. Transmastoid decompression as a treatment of Bell palsy. Otolaryngol Head Neck Surg 2001; 124:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/35\">",
"      Knox GW. Treatment controversies in Bell palsy. Arch Otolaryngol Head Neck Surg 1998; 124:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/36\">",
"      Fisch U. Prognostic value of electrical tests in acute facial paralysis. Am J Otol 1984; 5:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/37\">",
"      Shrode LW. Treatment of facial muscles affected by Bell's palsy with high-voltage electrical muscle stimulation. J Manipulative Physiol Ther 1993; 16:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/38\">",
"      Gittins J, Martin K, Sheldrick J, et al. Electrical stimulation as a therapeutic option to improve eyelid function in chronic facial nerve disorders. Invest Ophthalmol Vis Sci 1999; 40:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/39\">",
"      Targan RS, Alon G, Kay SL. Effect of long-term electrical stimulation on motor recovery and improvement of clinical residuals in patients with unresolved facial nerve palsy. Otolaryngol Head Neck Surg 2000; 122:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/40\">",
"      Ito H, Ito H, Nakano S, Kusaka H. Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand 2007; 115:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/41\">",
"      Nava-Casta&ntilde;eda A, Tovilla-Canales JL, Boullosa V, et al. Duration of botulinum toxin effect in the treatment of crocodile tears. Ophthal Plast Reconstr Surg 2006; 22:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/42\">",
"      Gilden DH. Clinical practice. Bell's Palsy. N Engl J Med 2004; 351:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9655/abstract/43\">",
"      Douglas RS, Gausas RE. A systematic comprehensive approach to management of irreversible facial paralysis. Facial Plast Surg 2003; 19:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5286 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9655=[""].join("\n");
var outline_f9_27_9655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EYE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GLUCOCORTICOID AND ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgical decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LONG-TERM SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5286|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/31/41468\" title=\"table 1\">",
"      House-Brackmann scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=related_link\">",
"      Patient information: Bell's palsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/13/32977?source=related_link\">",
"      Patient information: Bell's palsy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_27_9656="Lichen planus";
var content_f9_27_9656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lichen planus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9656/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9656/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9656/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9656/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9656/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/27/9656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen planus is a relatively uncommon disorder of unknown cause, most commonly affecting middle-aged adults. The disease course may be short or chronic. Buccal mucosal or genital involvement can be severe and debilitating in some patients because of pain. A general review of lichen planus is found here. The oral and vulvar aspects of this disease are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=see_link\">",
"     \"Oral lichen planus: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26361?source=see_link\">",
"     \"Oral lichen planus: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of lichen planus is not known. An immune-mediated mechanism involving activated T cells, particularly CD8+ T cells, directed against basal keratinocytes has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/1\">",
"     1",
"    </a>",
"    ]. Upregulation of intercellular adhesion molecule-1 (ICAM-1) and cytokines associated with a Th1 immune response, such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 alpha, IL-6, and IL-8, may also play a role in the pathogenesis of lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hepatitis C virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of hepatitis C virus (HCV) with lichen planus is controversial, and a cause and effect relationship is uncertain. A meta-analysis of primarily case-control studies conducted in a number of countries found a statistically significant association between HCV and lichen planus. Compared with control patients, the prevalence of HCV exposure was greater among patients with lichen planus (OR 5.4, 95% CI 3.5-8.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/5\">",
"     5",
"    </a>",
"    ]. A systematic review also identified an increase in the proportion of lichen planus patients that were HCV positive compared with controls (OR 4.80, 95% CI 3.25-7.09) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/6\">",
"     6",
"    </a>",
"    ]. However, subgroup analysis in both studies revealed that the strength of this association varied geographically, and was not statistically significant in all locations. Estimates of the prevalence of HCV infection among patients with oral lichen planus vary widely; studies have reported prevalence rates from 0 to 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should have a high suspicion for lichen planus in patients with hepatitis C who present with clinical features suggestive of the diagnosis. The meta-analysis cited above found that patients with HCV had an increased prevalence of lichen planus compared to controls (OR 2.5, 95% CI, 2.0-3.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/5\">",
"     5",
"    </a>",
"    ]. In a study from Italy, among 178 adults with HCV antibodies, five (2.8 percent) had oral lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/8\">",
"     8",
"    </a>",
"    ]. There are also reports of the development or exacerbation of lichen planus during interferon treatment for chronic HCV; the lesions improved when interferon was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Screening for HCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine screening for HCV infection in patients diagnosed with lichen planus is controversial. The variability in the prevalence of hepatitis C among patients with lichen planus in different geographic locations is likely to influence screening recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/5,6,10-12\">",
"     5,6,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a United States study in which 195 patients with oral lichen planus were prospectively screened for liver abnormalities, no liver abnormalities or antibodies to hepatitis B or C were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/10\">",
"     10",
"    </a>",
"    ]. This report suggested that routine screening for HCV is not necessary. Others have suggested screening for HCV in patients diagnosed with lichen planus, particularly those with risk factors for HCV infection, due to the risks of morbidity and transmission that exist with HCV infection and the presence of evidence suggesting an association between lichen planus and HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/5,6,12,13\">",
"     5,6,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are necessary to determine the value of HCV screening in the management of lichen planus patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen planus typically affects the skin, nails, mucous membranes (especially the oral mucosa), and the vulva and penis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/14\">",
"     14",
"    </a>",
"    ]. On the skin, it is most commonly expressed as an eruption of shiny, flat, polygonal, violaceous papules (",
"    <a class=\"graphic graphic_picture graphicRef70518 graphicRef58361 graphicRef50632 \" href=\"UTD.htm?20/63/21498\">",
"     picture 1A-C",
"    </a>",
"    ). Wickham's striae are characteristic white, lacelike patterns on the surface of the papules and plaques (",
"    <a class=\"graphic graphic_picture graphicRef61523 \" href=\"UTD.htm?27/20/27968\">",
"     picture 2",
"    </a>",
"    ). The flexor surfaces of the extremities, particularly the wrists, are common sites of skin involvement (",
"    <a class=\"graphic graphic_picture graphicRef63590 graphicRef76383 graphicRef50579 graphicRef53839 \" href=\"UTD.htm?27/31/28154\">",
"     picture 3A-D",
"    </a>",
"    ). Lesions are rarely asymptomatic. Most patients experience pruritus, which can be severe; lesions can become intensely painful if they ulcerate or erode. Lichen planus patients can exhibit the Koebner reaction, the development of skin lesions in areas of trauma. The Koebner reaction most often occurs as a result of scratching (",
"    <a class=\"graphic graphic_picture graphicRef68060 \" href=\"UTD.htm?7/25/7570\">",
"     picture 4",
"    </a>",
"    ). The disease usually heals with significant postinflammatory hyperpigmentation.",
"   </p>",
"   <p>",
"    Other cutaneous variants of lichen planus include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophic lichen planus, which is characterized by the presence of thick hyperkeratotic plaques, often on the anterior leg (",
"      <a class=\"graphic graphic_picture graphicRef54396 \" href=\"UTD.htm?23/6/23652\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Vesiculobullous lichen planus, in which blisters develop within the plaques.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When nails are involved, the disease spectrum varies from minor dystrophy to total nail loss (",
"    <a class=\"graphic graphic_picture graphicRef80419 \" href=\"UTD.htm?14/30/14820\">",
"     picture 6",
"    </a>",
"    ). The disease process in lichen planus of the nails primarily occurs in the nail matrix, making the disease inaccessible to topical treatments. Thus, this variant is particularly difficult to treat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=see_link&amp;anchor=H176463815#H176463815\">",
"     \"Overview of nail disorders\", section on 'Lichen planus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lichen planopilaris (LPP) is the term used to describe lichen planus that occurs on the scalp. Patients present with areas of hair loss with keratotic follicular papules that, left untreated, can progress to scarring alopecia (",
"    <a class=\"graphic graphic_picture graphicRef52848 \" href=\"UTD.htm?9/34/9767\">",
"     picture 7",
"    </a>",
"    ). Hair regrowth does not occur once follicles are destroyed.",
"   </p>",
"   <p>",
"    Lichen planus of the mucous membranes can occur in conjunction with cutaneous disease or independently. Mucous membrane disease may consist solely of lacelike Wickham's striae that are particularly evident on the buccal mucosa or can include papular, atrophic, or erosive lesions (",
"    <a class=\"graphic graphic_picture graphicRef76338 graphicRef62826 graphicRef54143 graphicRef80848 \" href=\"UTD.htm?12/54/13162\">",
"     picture 8A-D",
"    </a>",
"    ). Erosive mucous membrane disease is frequently painful and may lead to secondary complications including superficial candidal infection. Patients frequently report a persistent loss of appetite due to pain associated with eating. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=see_link&amp;anchor=H190861141#H190861141\">",
"     \"Oral lichen planus: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link&amp;anchor=H2#H2\">",
"     \"Vulvar lichen planus\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital lichen planus in men presents with violaceous papules on the glans penis (",
"    <a class=\"graphic graphic_picture graphicRef60985 graphicRef76913 \" href=\"UTD.htm?13/3/13369\">",
"     picture 9A-B",
"    </a>",
"    ), while in women lesions typically occur on the vulva. The vulvo-vaginal-gingival syndrome is an erosive form of lichen planus that involves the epithelium of the vulva, vestibule, vagina, and mouth; it is particularly resistant to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Although all three areas can be affected, the lesions may not be concurrent. The gingival epithelium is usually involved, but erosions, white plaques, or a whitish and lace-like reticular pattern may occur on the buccal mucosa, tongue, and palate (",
"    <a class=\"graphic graphic_picture graphicRef72786 \" href=\"UTD.htm?6/62/7141\">",
"     picture 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lichen planus may also involve the esophagus, presenting with or without symptoms such as dysphagia or odynophagia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/17\">",
"     17",
"    </a>",
"    ]. Possible endoscopic findings include pseudomembranes, friable and inflamed mucosa, submucosal papules, lacy white plaques, erosions, strictures, and other abnormalities (",
"    <a class=\"graphic graphic_picture graphicRef72940 \" href=\"UTD.htm?18/56/19334\">",
"     picture 11",
"    </a>",
"    ). Concomitant oral, genital, or cutaneous lichen planus is frequently present [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/17\">",
"     17",
"    </a>",
"    ]. The prevalence of esophageal lichen planus is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lichen planus usually is based upon the lesion's clinical appearance in a characteristic location. Wickham&rsquo;s striae will often be present in lesions on the buccal mucosa.",
"   </p>",
"   <p>",
"    A biopsy is often helpful in making a diagnosis of lichen planus. If a biopsy is performed, a punch biopsy of the most developed lesion is the preferred technique. Histopathologic examination of lichen planus reveals an interface dermatitis characterized by apoptotic keratinocytes (Civatte bodies) at the dermal-epidermal junction and an underlying band-like lymphocytic infiltrate (",
"    <a class=\"graphic graphic_picture graphicRef82025 graphicRef58826 \" href=\"UTD.htm?39/16/40202\">",
"     picture 12A-B",
"    </a>",
"    ). Hyperkeratosis, wedge-shaped areas of hypergranulosis, and elongated rete ridges resembling a &ldquo;saw-tooth&rdquo; like pattern are additional histopathologic features of this disorder.",
"   </p>",
"   <p>",
"    The differential diagnosis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug-induced lichen planus (also known as lichenoid drug eruptions) should always be considered so that the offending agent can be withdrawn when possible. The drug-induced form of lichen planus usually develops insidiously and can affect any area of the body surface (",
"      <a class=\"graphic graphic_picture graphicRef80165 graphicRef59258 \" href=\"UTD.htm?31/54/32617\">",
"       picture 13A-B",
"      </a>",
"      ). Oral lesions occur in 30 to 70 percent of cases; the mucosa may be painful and ulcerated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/18\">",
"       18",
"      </a>",
"      ]. Beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , nonsteroidal antiinflammatory drugs (NSAIDs) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/19\">",
"       19",
"      </a>",
"      ], angiotensin converting enzyme (ACE) inhibitors, sulfonylurea agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , gold,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      have all been associated with lichen planus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic graft-versus-host disease can produce a \"lichenoid'' eruption similar to lichen planus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Mucocutaneous manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary syphilis involves the palms and soles. The white, lacelike pattern on the buccal mucosa or genitals is absent. Serologic studies will differentiate the two. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of most cases of lichen planus is to remit within one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/21\">",
"     21",
"    </a>",
"    ]. The exception is oral lichen planus, which often is chronic and may be associated with an increased risk for oral cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26361?source=see_link&amp;anchor=H172227115#H172227115\">",
"     \"Oral lichen planus: Management and prognosis\", section on 'Prognosis and follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H714266\">",
"    <span class=\"h2\">",
"     Comorbid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of two case-control studies suggest that the prevalence of dyslipidemia may be greater among patients with lichen planus than among individuals without this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Additional studies are necessary to confirm an association between dyslipidemia and lichen planus and to explore the clinical relevance of this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a paucity of data on which to make evidence-based recommendations for the treatment of lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Only a few randomized, controlled trials have been performed, most of which were small and subject to methodologic error.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Body lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only blinded, placebo-controlled study that has been performed in patients with cutaneous lichen planus compared the oral retinoid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    with placebo and found the drug to have favorable results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/27\">",
"     27",
"    </a>",
"    ]. Most experts, however, recommend treatment with medium- to high-potency topical corticosteroids as first-line therapy for disease that is localized.",
"   </p>",
"   <p>",
"    We typically treat localized cutaneous lichen planus with 0.05 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate (15, 45 g), 0.05 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/56/24451?source=see_link\">",
"     diflorasone",
"    </a>",
"    diacetate (15, 30, 60 g), or another Class I cream or ointment twice daily. Efficacy should be assessed after two to three weeks, and patients should be cautioned about and followed for steroid atrophy subsequently.",
"   </p>",
"   <p>",
"    Oral glucocorticoids may be used in patients with generalized cutaneous lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/24\">",
"     24",
"    </a>",
"    ]. The optimal dose and duration of systemic glucocorticoid therapy is not known; it is reasonable to begin with 30 to 60 mg daily for four to six weeks and then taper over the next four to six weeks, although lower doses and shorter courses have also been proposed in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/24\">",
"     24",
"    </a>",
"    ]. Long term therapy with systemic glucocorticoids can lead to a variety of adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is a reasonable alternative to systemic glucocorticoids, particularly since, as mentioned, it is the only drug that has undergone the scrutiny of a randomized, controlled trial in patients with cutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/27\">",
"     27",
"    </a>",
"    ]. However, when considering either of these potentially toxic therapies, it should be emphasized that it is not clear that they alter the overall disease course since the natural history of cutaneous disease is to remit spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, these drugs should be reserved for patients with severe cutaneous lichen planus, and consultation with a dermatologist is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    is teratogenic, and is not recommended for women of child-bearing potential. Pregnancy is contraindicated for three years after discontinuation of the drug. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     \"Acitretin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other therapies with some reported efficacy include phototherapy (PUVA, UVB),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. Narrow band UVB phototherapy may be particularly useful in patients with widespread disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil has been used successfully in the treatment of two patients with extensive generalized lichen planus and one patient with resistant hypertrophic and bullous lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of a small uncontrolled study suggest that apremilast, a phosphodiesterase inhibitor that is not yet available for clinical use, may be beneficial for lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/35\">",
"     35",
"    </a>",
"    ]. Treatment with apremilast (20 mg twice daily for 12 weeks) was associated with clinical improvement in all 10 patients, including three patients who achieved at least a two-grade improvement in the physician global assessment score. Additional studies are necessary to explore the efficacy and safety of apremilast for lichen planus.",
"   </p>",
"   <p>",
"    Oral antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    hydrochloride 10 to 50 mg four times a day, as necessary) may be helpful in controlling pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genital lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids or topical calcineurin inhibitors are often used in the treatment of genital lichen planus. Patients may use water-based lubricants if needed for intercourse. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    may also be used on an as-needed basis for pain relief. The treatment of vulvar lichen planus is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Scalp lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of lichen planopilaris (LPP) can be difficult. Studies of effective treatments are limited, and the effect of treatment on the disease course is unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are no controlled studies supporting the efficacy of high potency topical corticosteroids or intralesional corticosteroids for the treatment of LPP, these drugs are often used as first-line therapies (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. In a series of 30 patients, treatment with topical corticosteroids for three months led to clinical improvement in 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a high rate of disease relapse has been reported with topical corticosteroid monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to respond to topical or intralesional corticosteroids, or who have rapidly progressive or extensive disease, may benefit from systemic therapy. In one retrospective study (n = 40), treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (200 mg twice daily) for one year led to significant improvement in symptoms and signs of LPP in 86 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/42\">",
"     42",
"    </a>",
"    ]. Other studies have reported lower rates of response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/38,43,44\">",
"     38,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    class antibiotics are an alternative for systemic treatment of LPP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/37,43\">",
"     37,43",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    (100 mg twice daily for three to six months) improved the signs and symptoms of active disease in 4 out of 15 patients treated with the drug in one retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LPP that is refractory to other therapies may respond to treatment with systemic immunosuppressants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/36,45,46\">",
"     36,45,46",
"    </a>",
"    ]. In a retrospective study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (0.5 g twice daily for four weeks, followed by 1 g twice daily) led to improvement in 10 out of 12 patients who completed at least six months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In a case series of three patients, lesions responded to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    at a dose of 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three to five months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/36\">",
"     36",
"    </a>",
"    ]. The potential adverse effects of cyclosporine make this drug a less favorable choice for treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatments with systemic retinoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , and an excimer laser have also been reported, although the benefits of these treatments remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypertrophic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional injections can help relieve pruritus.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    5 to 10",
"    <span class=\"nowrap\">",
"     mg/cc",
"    </span>",
"    is injected (0.5 to 1 mL per 2 cm lesion). Use cautiously in patients with darkly pigmented skin due to the risk of hypopigmentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259780496\">",
"    <span class=\"h2\">",
"     Mouth lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of oral lichen planus is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26361?source=see_link\">",
"     \"Oral lichen planus: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174264512\">",
"    <span class=\"h2\">",
"     Nail lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of lichen planus involving the nails is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=see_link&amp;anchor=H176463815#H176463815\">",
"     \"Overview of nail disorders\", section on 'Lichen planus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of the skin disease in patients with lichen planus, particularly when it affects the oral or genital mucosa, may lead to increased anxiety, stress, and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9656/abstract/48\">",
"     48",
"    </a>",
"    ]. Clinicians should pay particular attention to the management of psychosocial problems in patients with lichen planus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/28/6594?source=see_link\">",
"       \"Patient information: Lichen planus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lichen planus is a skin disorder that most commonly affects middle-aged adults. The disease may remit within one to two years or may be chronic. Clinicians should be aware of the potential for drug-induced forms of lichen planus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies have suggested an association of lichen planus with hepatitis C virus (HCV), although the strength of this association varies geographically. Further studies are necessary to determine if HCV screening should be performed in patients with lichen planus. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hepatitis C virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lichen planus may affect the skin, nails, or mucous membranes. Cutaneous lichen planus typically presents as pruritic, polygonal, violaceous papules",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plaques with an overlying white, lacelike pattern (Wickham's striae). Significant post-inflammatory hyperpigmentation is common. Cutaneous lichen planus may also present with hypertrophic or vesicobullous lesions. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lichen planopilaris is a form of lichen planus that affects the scalp and can lead to scarring alopecia. When lichen planus involves the oral cavity, it may present with only lacelike Wickham's striae or may include papular, atrophic, or erosive lesions. Genital areas can also be affected by lichen planus. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"       \"Vulvar lichen planus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Localized cutaneous lichen planus is usually managed with topical corticosteroids. Intralesional corticosteroids can be useful in patients with lichen planopilaris or hypertrophic lichen planus. In cases of widespread cutaneous disease, systemic medications (including glucocorticoids or retinoids) may be prescribed. Phototherapy has also been used for the treatment of widespread cutaneous disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical and intralesional corticosteroids are often used for the treatment of lichen planopilaris. Patients with refractory, rapidly progressive, or extensive disease may benefit from systemic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      or an oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      antibiotic. For patients who fail these therapies, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil is another option. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Scalp lesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/1\">",
"      Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Int J Dermatol 2009; 48:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/2\">",
"      Hussein MR. Evaluation of angiogenesis in normal and lichen planus skin by CD34 protein immunohistochemistry: preliminary findings. Cell Biol Int 2007; 31:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/3\">",
"      Chen X, Liu Z, Yue Q. The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication. J Huazhong Univ Sci Technolog Med Sci 2007; 27:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/4\">",
"      Rhodus NL, Cheng B, Ondrey F. Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus. Mediators Inflamm 2007; 2007:19854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/5\">",
"      Shengyuan L, Songpo Y, Wen W, et al. Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol 2009; 145:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/6\">",
"      Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004; 151:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/7\">",
"      Chainani-Wu N, Lozada-Nur F, Terrault N. Hepatitis C virus and lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/8\">",
"      Campisi G, Di Fede O, Craxi A, et al. Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity. J Am Acad Dermatol 2004; 51:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/9\">",
"      Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holterm&uuml;ller KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/10\">",
"      Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 2002; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/11\">",
"      Stojanovic L, Lunder T, Poljak M, et al. Lack of evidence for hepatitis C virus infection in association with lichen planus. Int J Dermatol 2008; 47:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/12\">",
"      Gimenez-Garc&iacute;a R, P&eacute;rez-Castrill&oacute;n JL. Lichen planus and hepatitis C virus infection. J Eur Acad Dermatol Venereol 2003; 17:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/13\">",
"      Lapane KL, Jakiche AF, Sugano D, et al. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 1998; 93:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/14\">",
"      Scully C, el-Kom M. Lichen planus: review and update on pathogenesis. J Oral Pathol 1985; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/15\">",
"      Pelisse M. The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus. Int J Dermatol 1989; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/16\">",
"      Eisen D. The vulvovaginal-gingival syndrome of lichen planus. The clinical characteristics of 22 patients. Arch Dermatol 1994; 130:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/17\">",
"      Fox LP, Lightdale CJ, Grossman ME. Lichen planus of the esophagus: what dermatologists need to know. J Am Acad Dermatol 2011; 65:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/18\">",
"      Thompson DF, Skaehill PA. Drug-induced lichen planus. Pharmacotherapy 1994; 14:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/19\">",
"      G&uuml;ne AT, Fetil E, Ilknur T, et al. Naproxen-induced lichen planus: report of 55 cases. Int J Dermatol 2006; 45:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/20\">",
"      Ball SB, Wojnarowska F. Vulvar dermatoses: lichen sclerosus, lichen planus, and vulval dermatitis/lichen simplex chronicus. Semin Cutan Med Surg 1998; 17:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/21\">",
"      Irvine C, Irvine F, Champion RH. Long-term follow-up of lichen planus. Acta Derm Venereol 1991; 71:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/22\">",
"      Arias-Santiago S, Buend&iacute;a-Eisman A, Aneiros-Fern&aacute;ndez J, et al. Cardiovascular risk factors in patients with lichen planus. Am J Med 2011; 124:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/23\">",
"      Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. Br J Dermatol 2009; 161:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/24\">",
"      Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/25\">",
"      Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011; :CD001168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/26\">",
"      Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012; 2:CD008092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/27\">",
"      Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol 1991; 24:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/28\">",
"      Gamil H, Nassar A, Saadawi A, et al. Narrow-band ultraviolet B phototherapy in lichen planus. J Eur Acad Dermatol Venereol 2009; 23:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/29\">",
"      Habib F, Stoebner PE, Picot E, et al. [Narrow band UVB phototherapy in the treatment of widespread lichen planus]. Ann Dermatol Venereol 2005; 132:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/30\">",
"      Pavlotsky F, Nathansohn N, Kriger G, et al. Ultraviolet-B treatment for cutaneous lichen planus: our experience with 50 patients. Photodermatol Photoimmunol Photomed 2008; 24:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/31\">",
"      Stefanidou MP, Ioannidou DJ, Panayiotides JG, Tosca AD. Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus. Br J Dermatol 1999; 141:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/32\">",
"      Akdeniz S, Harman M, Atmaca S, Yaldiz M. The management of lichen planus with low-molecular-weight heparin (enoxaparin). Int J Clin Pract 2005; 59:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/33\">",
"      Frieling U, Bonsmann G, Schwarz T, et al. Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol 2003; 49:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/34\">",
"      Nousari HC, Goyal S, Anhalt GJ. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol 1999; 135:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/35\">",
"      Paul J, Foss CE, Hirano SA, et al. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series. J Am Acad Dermatol 2013; 68:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/36\">",
"      Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen planopilaris. J Am Acad Dermatol 2003; 49:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/37\">",
"      Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR. A case-series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol 2007; 57:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/38\">",
"      Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg 2009; 28:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/39\">",
"      Sperling LC, Nguyen JV. Commentary: treatment of lichen planopilaris: some progress, but a long way to go. J Am Acad Dermatol 2010; 62:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/40\">",
"      Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol 2005; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/41\">",
"      Chieregato C, Zini A, Barba A, et al. Lichen planopilaris: report of 30 cases and review of the literature. Int J Dermatol 2003; 42:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/42\">",
"      Chiang C, Sah D, Cho BK, et al. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol 2010; 62:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/43\">",
"      Spencer LA, Hawryluk EB, English JC 3rd. Lichen planopilaris: retrospective study and stepwise therapeutic approach. Arch Dermatol 2009; 145:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/44\">",
"      Mehregan DA, Van Hale HM, Muller SA. Lichen planopilaris: clinical and pathologic study of forty-five patients. J Am Acad Dermatol 1992; 27:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/45\">",
"      Tursen U, Api H, Kaya T, Ikizoglu G. Treatment of lichen planopilaris with mycophenolate mofetil. Dermatol Online J 2004; 10:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/46\">",
"      Cho BK, Sah D, Chwalek J, et al. Efficacy and safety of mycophenolate mofetil for lichen planopilaris. J Am Acad Dermatol 2010; 62:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/47\">",
"      Kang H, Alzolibani AA, Otberg N, Shapiro J. Lichen planopilaris. Dermatol Ther 2008; 21:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/48\">",
"      Lundqvist EN, Wahlin YB, Bergdahl M, Bergdahl J. Psychological health in patients with genital and oral erosive lichen planus. J Eur Acad Dermatol Venereol 2006; 20:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/49\">",
"      Mirmirani P, Karnik P. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol 2009; 145:1363.58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9656/abstract/50\">",
"      Navarini AA, Kolios AG, Prinz-Vavricka BM, et al. Low-dose excimer 308-nm laser for treatment of lichen planopilaris. Arch Dermatol 2011; 147:1325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5662 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9656=[""].join("\n");
var outline_f9_27_9656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Screening for HCV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H714266\">",
"      Comorbid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Body lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genital lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Scalp lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypertrophic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259780496\">",
"      Mouth lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174264512\">",
"      Nail lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5662|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24160\" title=\"picture 1A\">",
"      Lichen planus arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/11/22709\" title=\"picture 1B\">",
"      Lichen planus hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/50/805\" title=\"picture 1C\">",
"      Generalized lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/20/27968\" title=\"picture 2\">",
"      Wickhams striae on plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/29/18898\" title=\"picture 3A\">",
"      Lichen planus flexures dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/42/29346\" title=\"picture 3B\">",
"      Lichen planus wrists fair skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/33/2576\" title=\"picture 3C\">",
"      Lichen planus wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/29/31187\" title=\"picture 3D\">",
"      Lichen planus wrist 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/25/7570\" title=\"picture 4\">",
"      Lichen planus Koebner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/6/23652\" title=\"picture 5\">",
"      Hypertrophic lichen planus lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/30/14820\" title=\"picture 6\">",
"      Lichen planus nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/34/9767\" title=\"picture 7\">",
"      Lichen planopilaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/30/20961\" title=\"picture 8A\">",
"      Lichen planus - oral Wickham striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/20/38209\" title=\"picture 8B\">",
"      Oral lichen planus - erosive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/10/27808\" title=\"picture 8C\">",
"      Oral lichen planus - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/30/42464\" title=\"picture 8D\">",
"      Oral lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/47/36597\" title=\"picture 9A\">",
"      Lichen planus penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/48/13059\" title=\"picture 9B\">",
"      Annular lichen planus - penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/62/7141\" title=\"picture 10\">",
"      Lichen planus tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/56/19334\" title=\"picture 11\">",
"      Esophageal lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/36/4681\" title=\"picture 12A\">",
"      Cutaneous lichen planus histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/59/8121\" title=\"picture 12B\">",
"      Cutaneous lichen planus interface dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/5/40021\" title=\"picture 13A\">",
"      Lichenoid drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35348\" title=\"picture 13B\">",
"      Lichenoid drug eruption hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5662|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=related_link\">",
"      Acitretin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26361?source=related_link\">",
"      Oral lichen planus: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=related_link\">",
"      Oral lichen planus: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=related_link\">",
"      Overview of nail disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/28/6594?source=related_link\">",
"      Patient information: Lichen planus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_27_9657="Overview of the management of vasculitis in children";
var content_f9_27_9657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of vasculitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9657/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9657/contributors\">",
"     David Cabral, MBBS, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9657/contributors\">",
"     Kimberly Morishita, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9657/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9657/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/27/9657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/27/9657/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/27/9657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is defined as the presence of inflammation in a blood vessel that may occur as a primary process or secondary to an underlying disease. Clinical symptoms vary widely; the various vasculitic syndromes are defined by both the type of pathological inflammation, and the type and location of the vessels, and this, in turn, determines which specific organs are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first priorities in management of a child with vasculitis are prompt recognition and timely treatment, as many of the vasculitides can be severe and life-threatening conditions if not appropriately managed. Specific treatments are determined by the type of vasculitis, the severity of the inflammation, and the particular organ systems affected.",
"   </p>",
"   <p>",
"    The overview of the management of vasculitis in children is reviewed here. The classification and the approach to evaluating childhood vasculitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=see_link\">",
"     \"Classification and incidence of childhood vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=see_link\">",
"     \"Approach to evaluating childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following principles are important to consider when managing a child with vasculitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differentiating vasculitis from other diseases that can either mimic vasculitis or cause secondary vasculitis.",
"     </li>",
"     <li>",
"      Defining disease activity and severity.",
"     </li>",
"     <li>",
"      Weighing the benefits and risks of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Differentiating vasculitis from other diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;In treating a child with vasculitis, it is critical to distinguish primary vasculitis from other diseases that can mimic vasculitis as well as from conditions causing secondary vasculitis, such as infections, drugs, malignancies, or connective tissue diseases (eg, systemic lupus erythematosus and juvenile dermatomyositis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/3\">",
"     3",
"    </a>",
"    ]. Making an accurate diagnosis is necessary to ensure that the appropriate therapy is initiated and to prevent the administration of medications that may be contraindicated. In children with secondary vasculitis, therapy is directed at treating the underlying disease (eg, infection or other rheumatic disorders). Thus, administration of immunosuppressive therapy may be appropriate in patients with primary vasculitis, but may have adverse (even catastrophic) consequences in a patient with secondary vasculitis due to a systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of some childhood primary vasculitides may be made clinically by recognizing the pattern of characteristic signs and symptoms of specific disorders. As examples, Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and Kawasaki disease, the two most common types of pediatric vasculitis, are diagnosed based upon a particular combination of findings or pattern of organ involvement (pattern recognition).",
"   </p>",
"   <p>",
"    Apart from these two disorders, other chronic vasculitides (eg, granulomatosis with polyangiitis [Wegener&rsquo;s], microscopic polyangiitis, polyarteritis nodosa, Takayasu arteritis) may present in a less obvious manner. Often, children present with either incomplete or overlapping diagnostic features compared to adult patients. As a result, many children with vasculitis have an \"unclassifiable\" disease. Therefore, in children, the diagnosis of vasculitis requires a high index of suspicion, a knowledge of the common clinical characteristics associated with vasculitis, as well as awareness of the potential conditions that mimic vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=see_link\">",
"     \"Approach to evaluating childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Defining disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease activity plays an important role in the treatment of the systemic vasculitides, both in interpreting the results of therapeutic studies and in directing the care for individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease activity is classified into the following three categories [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active disease &mdash; A patient has active disease when there is objective evidence of ongoing inflammation resulting in organ damage. However, determining this is not always straightforward because there is a lack of reliable disease activity markers for many types of systemic vasculitis. In addition, distinguishing active disease from chronic sequelae of the disease (irreversible damage), medication toxicity, and concomitant or secondary processes, such as infection, may be difficult. Because of the lack of reliable markers, assessment of disease activity often relies upon the clinical judgment of the treating clinician(s) based upon clinical findings (eg, signs, symptoms, disease tempo, and laboratory markers of inflammation, such as erythrocyte sedimentation rate or C-reactive protein). The ability to detect and quantify disease activity is important, as it impacts upon therapeutic choices. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Patient monitoring'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Remission &mdash; A patient is in remission when there is persistent evidence of the lack of active disease. The duration of required inactivity for remission has not been universally defined and varies considerably within the literature. In some studies, remission may be as short as three months for chronic vasculitides (eg, Takayasu arteritis) and 24 hours for acute conditions, such as Kawasaki disease. Remission may be further qualified as remission on or off medications.",
"     </li>",
"     <li>",
"      Relapse &mdash; Relapse occurs when major organ disease activity recurs following remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the management of childhood vasculitis, treatment is divided into three phases based upon disease activity as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy &mdash; Therapy is directed at stopping the inflammatory process in a newly diagnosed patient and putting the patient into remission.",
"     </li>",
"     <li>",
"      Maintenance therapy &mdash; Once the patient is in remission, therapy may be continued to maintain remission. In some cases, especially in diseases that are generally acute and self-limited (eg, Kawasaki disease), maintenance therapy may not be necessary and the patient may be in remission off medications.",
"     </li>",
"     <li>",
"      Relapse therapy &mdash; Therapy that is required to treat a reactivation of the inflammatory process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Weighing the benefits and risks of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When deciding upon therapy for any given vasculitis, one must weigh the benefits of a specific therapy and its potential adverse effects against the consequences of allowing the vascular inflammation to follow its natural history.",
"   </p>",
"   <p>",
"    Some vasculitides, such as Henoch-Sch&ouml;nlein purpura (IgA vasculitis), are acute and usually self-limited and uncomplicated. In these cases, it is usually unnecessary to even consider the use of potentially toxic therapies.",
"   </p>",
"   <p>",
"    Other vasculitides, such as granulomatosis with polyangiitis (Wegener&rsquo;s), follow a chronic relapsing course with ongoing serious morbidity and mortality risk due to end-stage renal disease and pulmonary hemorrhage. In such patients, long-term immunosuppressive therapy may be warranted in an attempt to halt disease progression.",
"   </p>",
"   <p>",
"    Children require special consideration regarding both short-term and long-term calculations of treatment risks and benefits. Both the disease and its treatments affect physical, social, educational, and emotional development, and long-term consequences should not be underestimated. Children inevitably have a long life expectancy ahead of them, so the significance of potentially life-saving treatment is magnified. On the other hand, children's developing organ systems are at risk of insidiously accruing a high toxic burden from therapies. With time, the potential long-term toxicities (eg, infertility, malignancy, osteoporosis, atherosclerosis) have a greater chance to manifest. Therefore, treatment of the rarer chronic vasculitides is best supervised by clinicians (eg, pediatric rheumatologists) with knowledge of the diseases, medications used to treat them, and their implications in a developing child. The importance of judiciously balancing the short and long-term risks of treatment against the short and long-term outcome of untreated disease cannot be overstated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Key questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, the treatment of primary vasculitic syndromes will vary based upon the answers to the following key questions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the disease active? Differentiate active disease from chronic sequelae of disease, medication toxicity, and other diseases, particularly infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Defining disease activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      How severe is the active disease? Fulminant life-threatening disease, or critical organ threatening disease, requires more aggressive management.",
"     </li>",
"     <li>",
"      What organ sites are being affected? Certain sites of organ involvement may not require or may not respond to systemic immunosuppressive therapy. As an example, subglottic stenosis in granulomatosis with polyangiitis (Wegener&rsquo;s) may be more appropriately treated with local therapy (eg, mitomycin-C injections",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mechanical dilation) than with systemic medications.",
"     </li>",
"     <li>",
"      What is the nature of the underlying disease process?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is the disease potentially life-threatening?",
"     </li>",
"     <li>",
"      What is known about long-term survival?",
"     </li>",
"     <li>",
"      Do relapses frequently occur in the specific disorder?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What are the data on different therapeutic regimens?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Has the regimen improved survival?",
"     </li>",
"     <li>",
"      What is the likelihood of inducing remission?",
"     </li>",
"     <li>",
"      What is the relapse rate?",
"     </li>",
"     <li>",
"      What are the known toxicities?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What accommodations should be made for unique characteristics of individual patients?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is there a history of medication toxicity or intolerability?",
"     </li>",
"     <li>",
"      Is there a contraindication to certain medications?",
"     </li>",
"     <li>",
"      Does the presence of previous organ damage restrict therapeutic options?",
"     </li>",
"     <li>",
"      Does the patient's age or gender constrain options?",
"     </li>",
"     <li>",
"      Do family preferences, tolerance of risk, or ability to comply with medication regimens militate for or against certain approaches?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of vasculitis depends upon the nature and severity of the disorder. Treatment options may include antihistamines, glucocorticoids, nonsteroidal antiinflammatory drugs (NSAIDs), or other immunosuppressive agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An overview of the general principles of the management of vasculitis will be presented here. Specific recommendations, including dosing regimens and detailed discussions of the individual disorders, are presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    As discussed above, the treatment of primary vasculitic syndromes will vary based upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific types of vasculitis categorized by the location and size of the involved vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. In particular, it is critical to distinguish primary from secondary vasculitis; in the latter case, therapy often is directed at treating the underlying disease (eg, infection or other rheumatic disorders). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=see_link\">",
"       \"Approach to evaluating childhood vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Localized (eg, cutaneous) versus systemic involvement.",
"     </li>",
"     <li>",
"      Acute self-limited (eg, Henoch-Sch&ouml;nlein purpura [HSP, also called IgA vasculitis or IgAV] and Kawasaki disease) versus chronic relapsing systemic disorders (eg, granulomatosis with polyangiitis [Wegener&rsquo;s], Takayasu arteritis, polyarteritis nodosa, and microscopic polyangiitis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General principles of management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cutaneous vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When vascular inflammation is limited to the skin, (such as mild cases of Henoch-Sch&ouml;nlein purpura [IgA vasculitis] or isolated cutaneous leukocytoclastic vasculitis), management consists mainly of supportive measures.",
"   </p>",
"   <p>",
"    In patients with mild hypersensitivity vasculitis due to a drug reaction, discontinuation of the offending drug may be adequate. Other supportive measures include antihistamines, which may relieve the itching associated with urticaria, and NSAIDs which may provide analgesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4070?source=see_link&amp;anchor=H11#H11\">",
"     \"Hypersensitivity vasculitis in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases of cutaneous vasculitis where the course is more prolonged or chronic, a trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14118?source=see_link\">",
"     colchicine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    may be added to supportive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Systemic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of primary systemic vasculitis in children varies depending upon whether the disorder is acute and self-limited, or chronic with potentially frequent relapses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acute and self-limited disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common primary vasculitides, Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and Kawasaki disease, typically present acutely and are usually characterized by a self-limited course. Management is based upon understanding the well-characterized course of these diseases, the risk of long-term sequelae, and the effectiveness of available therapy as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (HSP, or IgA vasculitis [IgAV]) &mdash; Since HSP (IgAV) is usually self-limited without major long-term complications, the management of affected patients is primarily supportive with therapy focused on symptomatic relief of arthritis and abdominal pain. The use of glucocorticoid therapy in children who do not respond to supportive therapy or who are thought to be at risk for developing permanent renal injury remains controversial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=see_link\">",
"       \"Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kawasaki disease (KD) &mdash; The acute clinical manifestations of KD are generally self-limited, however, cardiac complications (particularly coronary artery aneurysms) may develop and lead to significant morbidity and mortality. As a result, patients with KD are treated during the acute phase of the disorder to reduce the risk of coronary aneurysms. In randomized clinical trials, the administration of intravenous immune globulin (IVIG), in conjunction with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , dramatically reduced the risk of coronary aneurysms in children with KD. For children who fail to respond to the initial standard therapy of IVIG and aspirin, other immunosuppressive agents may be used. The initial treatment of KD, refractory therapy, and cardiovascular complications of KD are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"       \"Kawasaki disease: Initial treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40775?source=see_link\">",
"       \"Treatment of refractory Kawasaki disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"       \"Cardiovascular sequelae of Kawasaki disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chronic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike HSP (IgAV) and KD, other primary systemic vasculitides, (such as Takayasu arteritis, granulomatosis with polyangiitis [Wegener&rsquo;s], polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome) are characterized by chronic, often relapsing, disease courses.",
"   </p>",
"   <p>",
"    The most aggressive treatment for virtually all of these conditions would be the use of high-dose glucocorticoids in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to induce remission followed by initial maintenance therapy of lower dose glucocorticoids and continued administration of cyclophosphamide therapy. The dosage of these medications may be modified based upon the type and severity of the disease, rate of disease progression, and short and long-term side effects of the therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard initial glucocorticoid therapy for most of the systemic vasculitides is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided two to three times daily. In patients with severe or life-threatening disease, glucocorticoid therapy may be initiated intravenously with pulsed doses (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three days, maximum dosage of 1",
"    <span class=\"nowrap\">",
"     gm/day)",
"    </span>",
"    followed by standard doses. After one to two months of moderate to high-dose glucocorticoid therapy, the dose may be reduced and gradually discontinued as symptoms improve.",
"   </p>",
"   <p>",
"    While glucocorticoid therapy alone may be sufficient for mild and limited disease, an additional immunosuppressive agent is generally indicated for life-threatening organ involvement (eg, kidney, lung, or brain disease), or for glucocorticoid resistant or dependent disease.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is generally the first choice for an additional immunosuppressant agent to induce remission, as it has been shown to improve survival and remission rates in adults with primary systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    , a monoclonal antibody that depletes B cells, is challenging the role of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in the treatment of ANCA-associated vasculitis. Two randomized trials in adult patients have suggested that rituximab is an effective alternative to cyclophosphamide for the initial treatment of patients who have newly diagnosed disease or have relapsed following treatment with cyclophosphamide or other immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Both of these studies had limited duration of follow-up, and therefore, long-term efficacy and safety data are lacking. Thus, it is suggested that rituximab in pediatric systemic vasculitis be limited to patients with disease that is refractory to conventional treatment (cyclophosphamide and glucocorticoids) or those with relapsing disease in whom there is particular concern regarding cumulative glucocorticoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyclophosphamide toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A treatment protocol from the National Institutes of Health (NIH) for adult patients with granulomatosis with polyangiitis (Wegener&rsquo;s) combines daily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (oral dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) with glucocorticoids. Cyclophosphamide is continued for one year past remission. Although this regimen is highly effective in inducing and maintaining remission, the treatment-related toxicity of cyclophosphamide may be significant and includes short-term complications of bone marrow suppression with an associated risk of infection and hemorrhagic cystitis, and long-term complications of reduced fertility and increased risk of malignancy. An increasingly popular alternative to oral cyclophosphamide for the induction of remission is pulsed dose intravenous cyclophosphamide. In the randomized CYCLOPS (daily oral versus pulse cyclophosphamide) trial, this mode of administration was as effective as oral cyclophosphamide for induction of generalized ANCA-associated vasculitis in adults and was associated with less morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in adult systemic vasculitis have focused on establishing treatment protocols based on disease severity in an effort to minimize treatment-related toxicity and maximize disease control [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/15\">",
"     15",
"    </a>",
"    ]. The results of these studies have important implications for children because they demonstrate that milder, more localized disease can be treated effectively with less aggressive treatment protocols. As an example, the randomized NORAM (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    versus",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for early systemic disease) trial demonstrated that methotrexate was as effective as cyclophosphamide for the induction of remission in patients with early systemic ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/16\">",
"     16",
"    </a>",
"    ]. Other studies have also supported the use of methotrexate for induction in less severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatives to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    , are effective for the maintenance of remission and are increasingly being used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with primary chronic vasculitis should be cared for by experienced clinicians (eg, pediatric rheumatologists) who are familiar with the different primary vasculitides and their treatment. Management should always be based on the best available evidence published in the literature while taking into consideration individual patient factors, such as disease activity, severity, and tolerance of medications. Newer agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, as well as biologic agents (eg, tumor necrosis factor inhibitors and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    ), have shown benefit in small studies of various pediatric systemic vasculitides and are increasingly being used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations regarding specific treatment induction and maintenance regimens are discussed under each separate disease topic. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some manifestations of vasculitis (eg, neuropathy) may take months to recede because of the slow recovery of end-organ damage even when the underlying vasculitis is no longer active. In other cases, end-organ damage is irreversible resulting in permanent clinical abnormalities. For example, patients in remission may continue to have seizures or learning disabilities due to residual brain damage, or hypertension due to renal damage, both of which were incurred during the period of active vasculitis. These and other chronic complications need to be addressed and treated accordingly with both pharmacologic and nonpharmacologic therapies.",
"   </p>",
"   <p>",
"    The impact of these chronic disorders and their treatments upon the physical, educational, and psychosocial development of a growing child or adolescent should not be underestimated; it represents an additional arena of morbidity compared to adults with vasculitis. Important areas of potential concern include reduced physical fitness, excessive or inadequate weight gain, delayed puberty, reduced growth, impaired academic performance and career potential, limited participation in extracurricular activities, and depression.",
"   </p>",
"   <p>",
"    In addition to the pharmaceutical management of immunosuppression by the clinician, children with severe systemic vasculitis are best cared for by a multi-disciplinary team. Other medical subspecialists and health care professionals including nurses, physical and occupational therapists, social workers, and psychologists are team members who provide clinical care, counseling, referral to community services, and communication with the primary care clinician and school.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17062333\">",
"    <span class=\"h2\">",
"     Primary angiitis of the central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standardized protocol for treatment of primary CNS vasculitis in children. Acute ischemia due to medium-large vessel disease may cause irreversible damage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/26\">",
"     26",
"    </a>",
"    ]. For small vessel disease, however, reports suggest that there is potential for neurological recovery with early recognition and treatment of the inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. A protocol of immunosuppressive therapy for small vessel disease was evaluated in an open-label study at one center, with promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/30\">",
"     30",
"    </a>",
"    ]. However, further studies are needed to determine the optimal therapeutic approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of initial therapy is to induce remission of the disease. Once this has been accomplished, a balance must be achieved between maintaining remission and minimizing treatment-related toxicities. In order to do this, patients must be monitored on a regular basis for signs of disease activity as well as medication side effects. It is important to remember that most forms of primary systemic vasculitis (except for Henoch-Sch&ouml;nlein purpura [IgA vasculitis] and Kawasaki disease) tend to be chronic and relapsing. Distinguishing between active disease, chronic sequelae of disease and treatment-related side effects can be challenging; therefore, thorough and regular follow-up evaluations are necessary even when the patient appears entirely well.",
"   </p>",
"   <p>",
"    Patient monitoring relies upon some, but not all, of the procedures used in diagnosis including clinical findings, laboratory tests, imaging studies, and tissue biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=see_link\">",
"     \"Approach to evaluating childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain symptoms and signs, such as headache, claudication, skin lesions, and fever, are easily monitored. However, some features, such as neurocognitive changes, are more difficult to follow and are less clearly attributable to active disease alone. Other findings, such as decreased energy and fatigue, are nonspecific complaints that are commonly seen in the adolescent population. In addition, vessel damage may progress in some types of vasculitis despite a complete lack of symptoms and entirely normal acute phase reactants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/31\">",
"     31",
"    </a>",
"    ]. In these settings, monitoring disease activity with the aid of laboratory tests, repeat imaging studies, or formal cognitive testing by neuropsychologists is often essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory tests are used to monitor disease activity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute phase reactants &mdash; Erythrocyte sedimentation rate, serum C-reactive protein, and platelet count, among others, are nonspecific markers of inflammation. Elevations of these tests may be indicative of increased disease activity. Acute changes in conjunction with other clinical findings, or persistent abnormalities not accounted for by intercurrent illnesses or other factors, must be investigated carefully.",
"     </li>",
"     <li>",
"      Urinalysis &mdash; Monitoring with urinalyses on a regular basis can detect changes in the urinary sediment that may reflect active disease. Changes in the urinary sediment may also be due to persistent renal damage from earlier active disease or medication toxicity, such as hematuria from",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -associated hemorrhagic cystitis.",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibody (ANCA) titers &mdash; The utility of ANCA titers to predict active disease or risk of flares in ANCA-positive vasculitides remains controversial and is an area of ongoing study. Based upon currently available data, ANCA titers should not be used in isolation when making treatment decisions. This question is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Does a rise in ANCA titers predict a disease flare?'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Von Willebrand factor antigen, and perhaps other markers of endothelial cell disruption, may be useful for following damage to small vessels as occurs in vasculitis. In certain cases, such proteins may provide a more specific marker of disease activity than other acute phase reactants [",
"      <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory tests are also ordered for the purpose of monitoring medication toxicity, such as reduced cell counts in patients receiving immunosuppressive therapy, or elevated transaminases in those taking",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies of vessels or of major organs, such as the brain or lungs, may be necessary to distinguish whether clinical symptoms reflect active disease or prior damage. These studies, which include ultrasonography, echocardiography, computed tomography, and magnetic resonance imaging, may be used at regular intervals even in the absence of symptoms in order to monitor disease progression and response to treatment. As previously discussed, many laboratory markers of disease activity are nonspecific",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    difficult to interpret; thus, it is often necessary to use imaging as part of follow-up evaluations. Other types of studies evaluating end-organ function, such as pulmonary function tests, may also be helpful.",
"   </p>",
"   <p>",
"    Although conventional angiography may be necessary in the initial diagnostic evaluation of some systemic vasculitides, less invasive modalities, such as ultrasonography or magnetic resonance angiography, are preferred for continued routine monitoring, reserving more invasive testing for those situations in which more accurate imaging is required for critical therapeutic decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient had an initial biopsy and the findings were diagnostic, often little more is to be learned by repeating the procedure as part of ongoing monitoring. On the other hand, if the patient's original diagnosis is in question, a new illness is suspected, or ongoing disease activity must be distinguished from manifestations of irreversible damage, repeat biopsies may be useful. This is particularly likely to be the case with kidney involvement, though involvement of other organs also must be assayed in this way on occasion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Disease Activity Scoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formalized scoring tools, such as the Birmingham Vasculitis Activity Score (BVAS), are increasingly used to monitor disease and \"direct\" change of therapy for adults with vasculitis, both in the investigational and clinical practice setting. These tools are sometimes used for children with or without some pediatric-specific modifications, although their use in pediatrics is not validated. The development of pediatric-specific disease activity scoring tools is an imperative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes are dependent on numerous factors including the specific diagnosis, disease severity, involvement of major organs, response to treatment, and damage caused by treatment.",
"   </p>",
"   <p>",
"    The majority of children with primary vasculitis have a good outcome because the two most common disorders, Kawasaki disease and Henoch-Sch&ouml;nlein purpura (IgA vasculitis), are usually self-limited and only a small minority of children have long-term sequelae from either damage or ongoing disease activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link&amp;anchor=H15#H15\">",
"     \"Kawasaki disease: Initial treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the other primary systemic vasculitides, immunosuppressive therapy has improved survival and remission rates. As an example, prior to the introduction of the regimen of high-dose glucocorticoids and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , granulomatosis with polyangiitis (Wegener&rsquo;s) was fatal in almost all reported pediatric [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/34\">",
"     34",
"    </a>",
"    ] and adult cases. The reported median survival time was five months in untreated adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/35\">",
"     35",
"    </a>",
"    ]. The combination of glucocorticoids and cyclophosphamide (or more recently, other cytotoxic agents) has greatly improved patient outcomes. Similar therapeutic strategies have proven beneficial in the treatment of other systemic vasculitides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=see_link\">",
"     \"Treatment and prognosis of polyarteritis nodosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3015?source=see_link\">",
"     \"Treatment of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2008 systematic review of mortality risk in patients with systemic vasculitis that included both adult and pediatric patients reported the following five year survival rates: granulomatosis with polyangiitis (Wegener&rsquo;s) (approximately 75 percent), microscopic polyangiitis (45 to 75 percent), Churg-Strauss syndrome (68 to 100 percent), Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (75 percent in adult-onset, greater in childhood-onset), medium vessel vasculitis including polyarteritis nodosa (75 to 80 percent), Kawasaki disease (greater than 99 percent at five years), and Takayasu arteritis (70 to 93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite improved remission and survival rates, relapse is still common, especially when therapy is weaned or stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Flares of granulomatosis with polyangiitis (Wegener&rsquo;s) occur in up to 75 percent of pediatric patients as treatment is weaned [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/37\">",
"     37",
"    </a>",
"    ]. As a result, maintenance immunosuppression is commonly used in these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irreversible tissue damage is another crucial index of outcome. Measurement tools, such as the Vasculitis Damage Index (VDI), are widely used in adult chronic vasculitis to formally quantify damage sustained by either disease or treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/27/9657/abstract/39\">",
"     39",
"    </a>",
"    ]. These tools, or tools modified to incorporate measurements of damage unique to development and growth in children, have yet to be developed or validated, but are essential for the better understanding of childhood outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=see_link\">",
"       \"Patient information: Vasculitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is defined as the presence of inflammation in a blood vessel, which may occur as a primary process or secondary to an underlying disease. Prompt recognition and treatment of these disorders are important, as they can be severe and life-threatening conditions without appropriate treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Principles that are important in managing a child with vasculitis include (1) differentiating primary vasculitis from other conditions that can mimic vasculitis or cause secondary vasculitis, (2) defining disease activity and severity, and (3) weighing the benefits and risks of therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management decisions, including which therapy to use in an individual patient, are based upon answers to key questions regarding the course, activity, and severity of the disease, organ involvement, data about different therapeutic regimens, and individual patient factors (eg, age, gender, and previous medication adverse effects). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Key questions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of vasculitis depends upon the nature and severity of the disorder (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In children with secondary vasculitis, therapy is directed at treating the underlying disease (eg, infection, malignancy, or other rheumatic disorders).",
"     </li>",
"     <li>",
"      In children with cutaneous vasculitis (ie, vascular inflammation limited to the skin), supportive measures are generally all that is required. This includes the use of antihistamines, which relieves urticarial itching, and nonsteroidal antiinflammatory drugs (NSAIDs), which provide analgesia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cutaneous vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with acute self-limited systemic vasculitides, particularly Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and Kawasaki disease (the two most common causes of primary vasculitis in children), treatment choice is based upon understanding the well-characterized course of the specific disease, the risk of long-term sequelae, and the effectiveness of available therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Acute and self-limited disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with chronic or frequently relapsing vasculitis, immunosuppressive therapy is used to induce and maintain remission. Glucocorticoid therapy is the mainstay of therapy and in patients with mild or limited disease, steroids alone may be sufficient. However, in patients with severe or life-threatening disease, additional immunosuppressive agents, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , are generally needed.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       Rituximab",
"      </a>",
"      is an option in children with ANCA-associated vasculitis who have refractory disease despite conventional therapy or who have relapsing disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Chronic disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the patient is in remission, monitoring on a regular basis is required to detect signs of disease reactivation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      drug toxicity. Follow-up measures include monitoring clinical manifestations of disease (eg, fever, claudication, skin lesions, or headache), laboratory testing (eg, acute phase reactants and urinalysis), and imaging studies of vessels or of major organs to detect active disease versus residual damage. Tissue biopsy is usually not needed to monitor disease activity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome of childhood vasculitis is dependent upon the specific diagnosis, disease severity, whether major organs are involved, response to treatment, and damage caused by treatment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cassidy JT, Petty RE. Vasculitis and its classification. In: Textbook of pediatric rheumatology, 5th ed, Cassidy JT, Petty RE (Eds), Elsevier Saunders, Philadelphia 2005. p.492.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/2\">",
"      Dedeoglu F, Sundel RP. Vasculitis in children. Rheum Dis Clin North Am 2007; 33:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/3\">",
"      Hunder G. Vasculitis: diagnosis and therapy. Am J Med 1996; 100:37S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/4\">",
"      Roane DW, Griger DR. An approach to diagnosis and initial management of systemic vasculitis. Am Fam Physician 1999; 60:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/5\">",
"      Langford CA. Management of systemic vasculitis. Best Pract Res Clin Rheumatol 2001; 15:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/6\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/7\">",
"      Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/8\">",
"      Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis--is it time to reclassify? Rheumatology (Oxford) 2011; 50:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/9\">",
"      Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006; 24:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/10\">",
"      Allen NB, Bressler PB. Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndromes. Med Clin North Am 1997; 81:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/11\">",
"      Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/12\">",
"      Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/13\">",
"      Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2012; 51:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/14\">",
"      de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/15\">",
"      Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/16\">",
"      De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/17\">",
"      Jayne D. How to induce remission in primary systemic vasculitis. Best Pract Res Clin Rheumatol 2005; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/18\">",
"      Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997; 23:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/19\">",
"      Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/20\">",
"      Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/21\">",
"      Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/22\">",
"      Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/23\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/24\">",
"      Eleftheriou D, Melo M, Marks SD, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 2009; 48:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/25\">",
"      Wilkinson NM, Erendzhinova E, Zeft A, Cabral DA. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis. Rheumatology (Oxford) 2006; 45:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/26\">",
"      Benseler SM, Silverman E, Aviv RI, et al. Primary central nervous system vasculitis in children. Arthritis Rheum 2006; 54:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/27\">",
"      Bitter KJ, Epstein LG, Melin-Aldana H, et al. Cyclophosphamide treatment of primary angiitis of the central nervous system in children: report of 2 cases. J Rheumatol 2006; 33:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/28\">",
"      Benseler SM, deVeber G, Hawkins C, et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum 2005; 52:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/29\">",
"      Yaari R, Anselm IA, Szer IS, et al. Childhood primary angiitis of the central nervous system: two biopsy-proven cases. J Pediatr 2004; 145:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/30\">",
"      Hutchinson C, Elbers J, Halliday W, et al. Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study. Lancet Neurol 2010; 9:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/31\">",
"      Tann OR, Tulloh RM, Hamilton MC. Takayasu's disease: a review. Cardiol Young 2008; 18:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/32\">",
"      Falcini F, Generini S, Pignone A, et al. Are Angiotensin Converting Enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease? Endothelium 1999; 6:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/33\">",
"      Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/34\">",
"      Moorthy AV, Chesney RW, Segar WE, Groshong T. Wegener granulomatosis in childhood: prolonged survival following cytotoxic therapy. J Pediatr 1977; 91:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/35\">",
"      WALTON EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/36\">",
"      Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/37\">",
"      Rottem M, Fauci AS, Hallahan CW, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/38\">",
"      Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007; 57:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/27/9657/abstract/39\">",
"      Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997; 90:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6403 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9657=[""].join("\n");
var outline_f9_27_9657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Differentiating vasculitis from other diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Defining disease activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Weighing the benefits and risks of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Key questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cutaneous vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Systemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acute and self-limited disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chronic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17062333\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Disease Activity Scoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=related_link\">",
"      Approach to evaluating childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4070?source=related_link\">",
"      Hypersensitivity vasculitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=related_link\">",
"      Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=related_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=related_link\">",
"      Treatment and prognosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3015?source=related_link\">",
"      Treatment of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40775?source=related_link\">",
"      Treatment of refractory Kawasaki disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_27_9658="Gram stain lesion 1A answer";
var content_f9_27_9658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75923%7EID%2F54920%7EID%2F66744%7EID%2F78449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75923%7EID%2F54920%7EID%2F66744%7EID%2F78449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clostridium perfringens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of exudate from a bulla at the site of injection of intravenous drugs (x1000) shows large, Gram positive bacilli and the absence of leukocytes. Clostridium perfringens grew anaerobically from this specimen on blood agar. Clostridial infection may produce cellulitis or involve deeper tissues, as in gas gangrene.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clostridium perfringens on blood agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anaerobic culture of Clostridium perfringens on blood agar. The characteristic double zone of clear beta-hemolysis around a colony is clearly seen (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrotic muscle with clostridial gas gangrene",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin-stained biopsy of muscle (x400) from a patient with clostridial gas gangrene shows extensive necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clostridia in muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tissue gram stain of muscle biopsy (x400) from a patient with gas gangrene shows numerous Gram positive bacilli. Clostridium perfringens grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9658=[""].join("\n");
var outline_f9_27_9658=null;
var title_f9_27_9659="Impairment rating asthma";
var content_f9_27_9659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Impairment rating classes in asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Impairment class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        4-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        7-9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        10-11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        Asthma not controlled despite maximal treatment, ie, FEV1 remaining &lt;50 percent despite use of &ge;20 mg prednisone/day.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9659=[""].join("\n");
var outline_f9_27_9659=null;
var title_f9_27_9660="Preterm birth risk factors";
var content_f9_27_9660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for preterm birth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Non-modifiable risk factors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Prior preterm birth",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          African-American race",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Age &lt;18 or &gt;40 years",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Poor nutrition/low prepregnancy weight",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Low socioeconomic status",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cervical injury or anomaly",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Uterine anomaly or fibroid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Premature cervical dilatation (&gt;2 cm) or effacement (&gt;80 percent)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Over distended uterus (multiple pregnancy, polyhydramnios)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Periodontal disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ? Vaginal bleeding",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ? Excessive uterine activity",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Modifiable risk factors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cigarette smoking",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Substance abuse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Absent prenatal care",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Short interpregnancy intervals",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bacteriuria/urinary tract infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Genital infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ? Strenuous work",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ? High personal stress",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9660=[""].join("\n");
var outline_f9_27_9660=null;
var title_f9_27_9661="T3 resin test Normal";
var content_f9_27_9661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal T3 resin test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 318px; background-image: url(data:image/gif;base64,R0lGODlh+QA+AdUAAP///wCZ/wAAAMwAM/zw89YwWYCAgMDAwM8QQEBAQPbQ2eygs99ggBAQEPDw8ODg4CAgIKCgoNDQ0HBwcDAwMGBgYPng5pCQkNIgTVBQULCwsPLAzQBMfwByv+Dz/wAmP+JwjdxQc6DZ/+aAmQAvTzCs/xCf/2C//3DG/9lAZgATHwBCbwBfnwAJDwBpr++wwACP7wA5XwCF3wB8zwBWjwAcL+mQppmAhgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD5AD4BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4hwHiglAY6PkJGSk5QBJSgeiZp5HieVn6ChASeZm6ZxIiaiq6yPJiKnsWwirbWtsLK5ZbS2vaK4usFeHqq+xpUmpcLLWZ7Hz5MnzNNWHtDXksrU204o2N+OKNzjTY3g2CXk6knn4OvvRawd8x0wrCsfvvD7AKwC//9crGLBQR+/d/4EBGAhIF+ADiQ+rLAHA9+HggQfcnAR44PAUAcRrvoXgIaAGAFcCCCxYmUAFS04rFAR4INCDgJa2BQgA2RI/3UJ/9WwR0IABw4qFLZoEYNDT5sBcHYI0HIqqJ9ARwpoqcKezaNHA8wgkbSFDKhSowqw+gkruYQ1XZok0YFjTRYdbM5Au1Yt20pux8GV0UIAi6hJXRYVoOIw36lprwbe1u7bZMqVr12mllnzZmbmOvtK93mZN9G+xJUWZg11L22rczlzzUpabNbFaIdKdnsZL92ggPUO9hv4JOHDExhxcKC5cwcPIhi48MBPKuORXg0fkkGDAA0ZiBwACPBAAoANHPjphN0Rqe1DHpxPUH0I8/ECmjvQ4MABhfyALBKaaJfAtt0E/1EwwRH/EPGAAQ0oB99tBwAgAAAVGtHgEBIkEP+hehNSmMSGRBgggAEhpjgEiRBMAKEAEaioIokZ/NMAijLmuI4EF+joIwD+xfijjP4JIMGQXnQoJDMVkIjkFuMtyMwE/0j45BYPCGBlMBEAJOWVW2i5jHcALQlmFmIGI0ED5B15phZp6gIBeRe+CWcDwjhgYpV2anHeMvg1UEGfWfwZjANzGgAdoVgYqguVEDDqZ525kOmmpFc4GsuaJ2JaqJGyICpAeJ5iQWWGphRJAYilWmEiqpqoymqrVbya6n8NXEprrQBqIkGCuu5Kha2JcLqqsFgQe8gFVc6K7LC9FuJAjQIM+myy0Q5ywJwNmHktr7AC4gCVAlAQ7LfQhuv/x7b/fInuFcr68QC1FKj7brp/6GkjjvdmEW8eerJZbX39+pvtHQFXaW/B4ObxoMAJLMxww3ZI0KTCE3vx7xsORPDfPxlInLGrB7dxQAUCNzABwSN30aTIZUgwwZz/UBCBsy1zcR7LaBwwM0At8pyzF5qW0THK6FUA89CTGq0BguS1uDTTWxTNRXRQk5fABedSPYbVVkiggQEe0qng1F5/8Z8VB4ydwcfkRWgA2mmHUW4TErRtANnn0fkPBAkYoIHQdbMhAAR7J853An37TR4FgV9wAM6Fw+H45YAn4GIEBxBeOR0OHK743ho45/nnfESJeizj8bu6Jq1nTEABC2zD/2yPDM8+wAC1T7Pxt7ojsHvvy/z+rO4FEMDA8Mzs3C/yBAixPAIKLAM2stATMX31wcx5b/ZFhDAA9cHEeS34RQTPvSzmY1/AAMknob4sqp//fvxKzH9K7MffHz0T+tuEibzVKvQB8H3kE2DJPGXAJgQQEc7bVQOd8EBDrE2C/qvC/BrHJwBI4B90MxwFhDVBKKhPOvMxQIxEtcA5ZGlLBcygBhFoAQCYiF8z+08I1cA/EsqQCrrDgAVuKITxmKeFcjAR7twHv/9NIYgEICIAPFQ2c+WhSemxXxOpsD0bdgoA0jHAnCpwOjj0bYRaxB8UQLC7DQhBikM4zw7TQB53+f9wi09YAPOE8IDOFSFvlJNDlsijAeD9cAkb2B0IEOEdA1wsV4bEoxIUIDwGJMJE/PnYsdLoxCMQAAOSTIIFOnkH5zlAYNbipChBmUD5FaAANcxDA/AkhA/+o5CRVKMRKkgE3YWSDi8kArME0IAyMvCQ6UPg+nqJQGTKoUuum2LN3lVCIQTPjUVQZjXd8LIinLJd1HTmEAiQgj1Kb3zc2yYbLlgE/CAxhr8swvJ4d84BLFOdaQgdGo2wpyyiS53zXEBAdynONXjHjkT4GKn+WdB6mjOZ8VxDk3B5hAcIjIBM1KURBurKiKZhToEUwjCL+b2GAmABNjigR80QzCVQC4b/qrwCPsVwOyZ8UwBLZOhKnwC9CDDup1aqQAIwioUadc0IZCJpSXdKwfdh4AYJwBXj3viPaGYhdJFyAr0KNtMlQBFDcfrgf6yKhS4hNAk3zalONRqFLoLVShTIABy3YFQoBMqYtOrqEdg4AGy+VaQCmMB85qgErErhpbkzKRL0SM8hjEdCPk3AnCBAVCqYVQppTSxTi5DIASxSPO2baxb+c9QlJBWveVXsECg5AEsW4UHeOsDcrna4KlBroc9TLWvZegYqqRUKN6Vobpkqvr624ZshbcIwIZDcjJISoo1VA7NSWYW+nXWtz5XnQ5WwgOxSYU6lfYItQTUxfHKUu5tt/0KXYAqt9g2Xt9rb3QiU0Fn4LfO77wQuzSqbS+8OYQS7c60RLCC8ECjTCuvlQlKb2z+mMlbA4/QfL53wTcIqwbotw+eDtYuAWE6YCVRi7xUGKQDUOncJjMUfgO3JTHRGwZYmjsKeRLxU+K5WeMl7wXYB8OEjFImsVxWYhY/J1N1WEgk9LkKT9vmFLtU2Z/hk7QBSkD8E+tUIQnJyeEf7j99q1sZCUAAGMOBfaxaXeEQ4KH74q4VAMbi/Xo0lE84rhJuyibpioBaQuaraJ5RzAHIGALVAdgYSx7jBYH6CjqMLADKhZ8tcIBeeR6bXJLAWwhaNGxnPcNNDI7rMXn0flf+J0LgbvbkLe8ItlPt8hHKSWZj7OrUXbjrk1Ka3CGxsJQAsijhZg2GYNC4vq4XAWDQDoAJsRgPNam3rRN/Ys3twcrCFvdlPTpmCoBbDsuuGTwuA0tkWeGW2wSDtwuFTnda+tRe2zW3FVjOIw+ZCuc3tbnFur9JcoBmkqZ3oBs4znfHWgpMnTbVz/7DYLXa2FwTm6RqDOnuLni9EFc6FPRG84PWG3waO7MmAX+GmvuYzU3157Y5SXAvk2jPTzv3th3u8CoOkJeq6HYJAI/nlVbhYsletbpOPmwu2zOrq8E3QnlcNhK/jMc6JvgUnq/pzTGd6vv/RcH7/3Jo438KeVJ7/Nr1KvQuhe3LSlV7trLvslmPH+k6//gX8PH3oBWU7GGhWdUo7U+6/rmraIxxKvINhkELfO/j8HgZq7bvdTSR8GMh08dchz+xmYJPM9652o7PhYsKl/OxO/gZbNj7pBLh6HGgWcsrXgVw7Nz0ebPl21fuB9K4fBLkyH/s+eL72guAW7gNxMWbvHg1kuu7v7zDN4feBWnU3PhqGmXrlt2GQn3f+6IkpfT1c7PDVV4OTvZx9OAyy9d1/g+7DX4eLJZ/8Tf5H89FPBlsKn/1qYNO04X+GvtE/DnvC/v3BQKb1798Lg/R+/0cGHTSAa3Aek2eAaHAxpVdeNicIe+J73xJu/5xnB2vmeO9jeXNgS1zHcwWAY6JXB/8QfRnmP5dWCPIHdTJ0goNwHoHnNQa0YYJgf4jHVggXCHtSg951g38QgTBoUnTGB8MkgZIyU27VB/hBhISiV0e4B/jBfe91dUk2B/jRgTHFU05lARyUJrakhFQwSFZ4YlEQPBaAQlqiQkDCbm6gd7LzckcIRzmUX2XAhlYnBXx1ZVJkRHJkOV8kOy0HBTxIVThCRWxiRWvYhxmzWz/XWZ9VIl8URmN0fmiCiIkIgkzAgkUgWnv4BnTYMoqYP39oBH3EM4DEh2H4LZ+IBN6WXqM0B52YM6nYcSP3Sg+4BmCYNrFYdDbmSxXYdv+vODS5OHHZFTyQhwUXWDfBmHCkpD6KRwVJWDnJyHdqpD/NKAU+CI2WeHN4dGDSGIJaR3WoE41qlzxNOI7emAUX8zriSHbCw2Ky2IuNQn3qmI2eBEqMpovnaAUpmHTrGG7G9o75SAUjmHbriIUaOAVVuHeYaAXVmARDSHkLOUMDIERkQC4N6IkcdwVOFT2CBVRS4gCMo39G8B8vmHadBWFT4FaCNVmaIwR9M2RhB36vI4NTsGJX5kX8cgENMCdDRiZQmHQ0CYg7JkUWdQGbOAXkIpJ1E5RNEJGCKAQZcCORSAW48ntMqQQENgAhgARS1JGFqJS7NpBWGWAOVFCaKIf/SMB8xneVRlBc9yUes0UE0lF3H3ORlcOWRLBbtfgF3yd9ePlsuoaVAYl61feXaheYRxBuGPCWSwAiktd9hsmO/9hL9oiYSiAoeyKAuBeZBHBm2ogBVuYEJAaO4ReZADBPEsdhCuBLk2kE7gRO5GeafIWSd2hNQXgEe1Izdrl3pkmTgXiaiuRSj0Z/jNWISZBiBMCIe0WWSUAz5EWcO2YEGwc/GWkED5ZdYQcjA/ibRyBlYIacrvmL0HmP3Tlm2TadGjVdCigEfNWavbSXRsBaFDkEQrWeQ3CbViA+r0afu6l8+FmTLkYE/el8/wkFneWe9hlf5AkFWYmSCZoEBcoE//fzoE8QoRA6PvBJoRsVnehlXBpaoRzancKTmh/qBBZqTaC0lQ4UkOF3oqtYAIxZBBTIot3notyojQdJfif6YfCWoy0aonxnmdpUjNW3ozd6TgnUkMM3Tzcpi63EpMpYokgaoy2GAG60Yv+opL9Xjp5UXP+ppbvHpUcwT9BmchlqgFN4Tg6Kj1KapifVlDh2pmh6pFVQkPbpppNEj1J6mFTKBC+gp3vKp1PAWCFAo/eHp0Ngmm1Kpx26poEKUZZpBCvmqI8KqX0KnANAopVaZQE6pkC6qZbqqQsKqh2la535qaRadEmKQC+QqlLAjIzqqmU5kbEqq7Paqbb6qq90qRG5ugSt2KvAGqzCOqzE2qtBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiolabeled T3 (*T3) first interacts with available binding sites on binding proteins; then a resin is added which binds the remaining tracer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9661=[""].join("\n");
var outline_f9_27_9661=null;
var title_f9_27_9662="Trigger event vs LQTS genotype";
var content_f9_27_9662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Triggers for cardiac events in long QT syndrome are related to genotype",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 670 patients with a long QT syndrome (LQTS) and known genotype, the occurrence of a cardiac event provoked by a specific trigger (exercise, emotion, and sleep/rest without arousal) differed according to genotype. LQTS 1 patients experienced the majority of their events (62 percent) during exercise, while only 3 percent occurred during rest or sleep. These percentages were almost reversed among LQTS 2 and LQTS 3 patients, who were less likely to have events during exercise (13 percent) and more likely to have events during rest or sleep (29 and 39 percent, respectively).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Schwartz PJ, Priori SG, Spazzolini C, et al. Circulation 2001; 103:89.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9662=[""].join("\n");
var outline_f9_27_9662=null;
var title_f9_27_9663="Tubal ring sterilization C";
var content_f9_27_9663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tubal ring sterilization by laparoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_27_9663=[""].join("\n");
var outline_f9_27_9663=null;
